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In 2003, a distinguished group of university leaders, educators and business representatives came together 
for a unique and unprecedented summit, spearheaded by Harvard Business School professor Michael 
Porter and hosted by the presidents of MIT and Harvard, Susan Hockfield and Drew Gilpin Faust. This 
was the same year those two universities played a major role in the international team that cracked the 
human genome. 
The summit’s purpose was to discuss the state’s life sciences “super cluster,” meaning all of the many 
sectors that are involved in the life sciences. Everyone attending agreed that strengthening the life sciences 
was not only smart and played to our state’s strengths, it was crucial to our future global competitiveness. 
It could mean jobs for hundreds of thousands and billions added to the Massachusetts economy.
While the summit was stimulating, there was no established vehicle to build on the momentum that it 
generated. And so, in 2005, the Boston Foundation provided a grant of $125,000 to create the Massachusetts 
Life Sciences Collaborative. The Organizing Committee for the new group included the leaders of all of the 
Boston area’s major universities, teaching hospitals, life-sciences companies and venture-capital firms. 
In March of 2007, Governor Deval Patrick spoke at one of the Collaborative’s meetings about the 
importance of the life sciences to the Commonwealth. He previewed an announcement he would make 
publicly later that year about the creation of a new Massachusetts Life Sciences Initiative, which represented 
a 10-year, $1 billion investment to enhance and strengthen the state’s leadership in the life sciences.
The Boston Foundation was honored to play a major convening role in bringing together the stakeholders 
for those early discussions. And now we are proud to publish this first report on the Massachusetts Life 
Sciences Initiative and the work of the quasi-public agency charged with carrying out its mission. 
We have published many reports researched by the lead author of this report, Barry Bluestone, Director of 
the Kitty and Michael Dukakis Center for Urban Affairs at Northeastern. Reports from the Dukakis Center 
are always thorough and compelling, but not all of them carry good news. This one does, especially when 
it comes to economic impact. The $56.6 million Massachusetts awarded in tax incentives to life sciences 
firms between 2009 and 2011 has created 2,500 jobs, which should generate more than $266 million in 
wages and salaries during the next five years. In fact, the Commonwealth’s life sciences super cluster has 
risen to number one in the nation in terms of per capita employment, with close to 14,300 jobs for every one 
million residents. 
These jobs are not just for workers with advanced degrees: at least one in five require no more than 
a two-year associate’s degree and another 48 percent require just a bachelor’s degree. For the Boston 
Foundation, this confirms our deep investment in supporting the full education pipeline and the 
importance of preparing college students for well-paying jobs in a field that will only grow. 
Estimating the economic impact of this life sciences super cluster is within our grasp. Evaluating its 
broader value to society is daunting because of the almost limitless potential it has for improving the lives 
and well-being of people here in Massachusetts and around the world. 
Paul S. Grogan 
President & CEO
Preface
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Executive Summary
This report provides an up-to-date, independent 
evaluation of the $1 billion, 10-year Massachusetts Life 
Sciences Initiative and the Massachusetts Life Sciences 
Center (MLSC) charged with the responsibility of carry-
ing out its mission. The initiative was established in July 
2008 by Governor Deval Patrick’s Administration and 
the Legislature to encourage the growth of discovery 
and production in the life sciences, including biotech-
nology, pharmaceuticals, medical diagnostics, medi-
cal devices and bioinformatics in the Commonwealth. 
Based on the region’s existing comparative advantage in 
life sciences research and development (R&D) emanat-
ing from the laboratories of its leading universities 
and medical institutions, this substantial infusion of 
public funds was undertaken with the ambitious goal of 
making this cluster of industry sectors the most success-
ful in the world. 
This evaluation comes at a propitious time, given the 
state of fiscal affairs in the Commonwealth and the 
nation. Virtually every unit of government is scrutiniz-
ing the use of each tax dollar to ensure that public reve-
nue is being spent effectively and efficiently. Put simply, 
our goal in this evaluation was to gather as much data 
as possible to assess whether the Commonwealth’s size-
able commitment of public resources is paying off in the 
form of a life sciences “super cluster” capable of attract-
ing massive amounts of investment dollars, generating 
well-paying jobs for Massachusetts residents and yield-
ing additional tax revenue for the Commonwealth.
The Life Sciences Super Cluster and the MLSC
After it was created, the MLSC sought to develop as a 
key element of its strategy the creation of a collaborative 
“ecosystem” encompassing all aspects of the state’s life 
sciences. It would do this by encouraging the develop-
ment of a dense, highly connected community of schol-
ars, entrepreneurs, industry leaders, venture capitalists 
and government officials who were all dedicated to the 
success of this sector. Unlike many narrowly focused 
state economic development initiatives, the Center has 
chosen to guide its investments with a broad range of 
strategic priorities geared to enhance all aspects of the 
life sciences cluster. These include:
n funding translational research that converts new 
discoveries into marketable products and services
n investing in promising new technologies
n ensuring worker skill acquisition that aligns with the 
needs of life sciences industries
n creating new infrastructure with shared resources to 
accelerate life sciences innovation
n building partnerships among segments of the local 
and international life sciences communities
To accomplish these goals, the Center relies on a portfo-
lio of seven distinct programs. These include:
Cooperative Research Grants to support industry-spon-
sored research at universities in order to facilitate scien-
tific discoveries that lead to medical applications. These 
grants match industry contributions dollar for dollar. 
Internship Challenge Program to provide funds for 
interns working at start-up and smaller Massachusetts 
life sciences companies. 
New Investigator Grants to spur innovative research 
and advance the careers of new investigators working 
on cutting-edge research at academic research centers in 
Massachusetts.
Life Sciences Accelerator Loan Program to make loans 
available to early-stage companies and help leverage 
additional sources of capital.
Small Business Matching Grant (SBMG) Program  
to provide matching support to firms on the verge  
of commercializing new technologies developed  
with Phase II or Post-Phase II federal Small Business 
Innovation Research (SBIR) awards or federal Small 
Business Technology Transfer (STTR) grants.
Life Sciences Tax Incentive Program to offer a combina-
tion of 10 competitively awarded tax incentives avail-
able to companies that meet specified hiring goals. 
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Capital Projects Fund to provide capital for equip-
ment and supplies for high schools in Gateway Cities, 
vocational/technical schools, and community colleges; 
and for capital projects at academic/research institu-
tions, business incubators, and other not-for-profit 
organizations.
Between 2008 and June 30, 2012, the Center directly 
invested or committed more than $300 million in state 
funds that have leveraged more than $1 billion in third-
party investments by private businesses, the federal 
government and foundations, according to the MLSC 
FY2012 Report. Table 1 provides a breakdown of  
these investments.
Special Features of the Massachusetts  
Life Sciences Center
Our analysis revealed that, aside from its extraordinarily 
broad mandate, there are other factors that make the MLSC 
quite different from most government subsidy programs.  
First, the MLSC operates under a Board of Directors that 
includes state government officials, but also industry 
CEOs, leaders from academia and medicine, bioscience 
researchers and others who have great knowledge of the 
life sciences. 
Second, MLSC accelerator loans and other investments 
are reviewed by a panel of more than 200 specialists who 
advise the Center’s Scientific Advisory Board (SAB), 
which itself is dominated by academic researchers, 
industry scientists, and private venture-capital experts 
who together can judge both the scientific and economic 
potential of an MLSC investment. Accelerator loans are 
also reviewed by private venture-capital experts who can 
assess the economic potential of recipient firms. 
And third, the Center insists on accountability in terms 
of private sector investment matches. The Center also 
retains the power (and has utilized it) to “claw back” tax 
incentives if and when specific job creation goals are not 
reached by grant recipients.
We discovered from our interviews with life sciences 
executives, trade association leaders and members of 
the MSLC Scientific Advisory Board that the high level 
of professionalism associated with the Center’s expert-
based review process has resulted in MLSC invest-
ments that appear to have a high rate of return for the 
Commonwealth. We will return to this point, but must 
first touch upon a finding even more important than the 
measured rates of return to specific MLSC programs. 
New vs. Old Growth Theory
To properly assess the value of the Life Sciences Initia-
tive and the MLSC, it is useful to place its activities in the 
context of economic growth theory. What is now known 
as the “old growth theory” suggests that economic pros-
perity springs from the accumulation of ever greater 
stocks of the fundamental ingredients of production: 
capital, labor and natural resources. Those countries that 
find ways of increasing investment in plant and equip-
ment, adding to labor supply and extracting more natural 
resources are the ones that will become more affluent. 
While not completely discounting this approach to 
growth, a “new growth theory” has evolved that places 
technological progress at the very epicenter of growth 
dynamics—even more important than capital, labor and 
resource inputs. Advances in technology and interdepen-
dencies between new ideas and new investment provide 
the basis for entire new industries and products that 
generate additional wealth and raise living standards. 
Innovation-based growth is so powerful because it 
avoids the classic problem of diminishing returns on 
any given investment. With this type of growth, once 
the fixed cost of creating a new technology has been 
incurred, the formula can be used over and over again at 
little or no cost. As such, there can be increasing returns 
paying enormous dividends to society. 
Moreover, the new innovation-based growth theory 
TABLE 1
Distribution of MLSC Investments by Dollar Amount  
(June 2008–June 2012)
Capital Projects (12) $186,950,000
Company Grants and Accelerator Loans (31) $22,907,000
Academic Research Grants (35) $23,346,344
Tax Incentives (56) $56,595,093
Interns Funded for Workforce Development (884) $6,903,164
Equipment and Supply Grants for Schools (32) $3,333,675
Other Grants/Business Plan Competitions $1,540,000
TOTAL $301,575,276
Source: Massachusetts Life Sciences Center, 2013
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posits a strong reciprocity among the rate of skill acqui-
sition by workers, investments in new capital and new 
inventions. Thus, programs that combine incentives for 
innovation along with resources to augment human 
capital should fuel rapid economic growth more than 
anything else society can do to promote prosperity. 
What is special about the Massachusetts Life Sciences 
Initiative is that it focuses explicitly on increasing the rate 
of innovation by encouraging more research and develop-
ment (R&D) in the life sciences and helping small firms in 
this super cluster convert basic research into marketable 
products and services. New growth theory posits that this 
activity is the very fountain of economic growth. 
Has the MLSC Been Successful?
Unfortunately, keeping score on the success of innova-
tion is difficult. Instead of a more-or-less certain return to 
a given infusion of capital under the old growth theory, 
under the new growth theory, innovation tends to deliver 
stronger long-term growth but it is “lumpy, discontinu-
ous, and nonlinear.” There can be a long gap between the 
time a new innovation is first incorporated into produc-
tion and the time that it pays off in terms of increased 
productivity, output and jobs. In the short term, it can be 
discouraging, as investments in fundamental innovation 
usually have little immediate payoff. It will take decades 
to realize the full benefits to humanity and the economy 
from the advances now being made in drug discovery, 
medical diagnostics and medical devices.
What we can do is measure the short-term direct 
benefits of MLSC investments and consider the views 
of experts as to whether the Center has indeed played a 
critical role in creating a life sciences “ecosystem” that 
attracts investment and generates jobs in this sector.
Short-Term Benefits
As for the short-term benefits, we conducted a cost-bene-
fit analysis of the Center’s tax incentive program. Accord-
ing to our analysis based on MLSC data, the total value of 
tax incentives outstanding to Massachusetts life sciences 
firms as of June 30, 2012 was $56.6 million. Our best esti-
mate is that a little over 2,500 jobs were created as a result 
of these incentives. Given the average $105,000 salary of 
these jobs, we predict they will generate more than $266 
million in wages and salaries during the next five years. If 
our analysis proves correct, these workers will pay more 
than $93 million in state personal income and sales taxes 
during that period. As such, assuming all of these jobs 
were directly related to the tax incentives and that these 
jobs last at least five years, every dollar of tax incentive 
will repay $1.66 to state coffers, as Table 2 reveals. This is 
an outstanding rate of return. 
What is more, our analysis suggests that these jobs will go 
to a broad array of workers, not just those with advanced 
degrees. As Figure 1 reveals, more than one in five jobs in 
life sciences firms require no more than a two-year associ-
ate’s degree and nearly another half (48%) require no more 
than a bachelor’s degree. Thus, the short-term benefits of 
MLSC tax incentives seem to have heavily outweighed the 
costs and the job benefits are broadly shared.
The Unique Growth Pattern of  
Regional Life Sciences Clusters
The most important benefits stemming from MLSC activi-
ties, however, will come in the future. This is due to the 
unique growth pattern of highly innovative sectors like 
the life sciences. The regional concentration of life-sciences 
companies happens in a very different manner than in 
other industries. In the case of traditional industrial sectors 
such as auto, aircraft engine, financial services and the like, 
Less than 2 years 
beyond HS
4%
HS or Less
15%
Ph.D.
7%
Professional
Degree
3%
M.A. / M.S.
19%
B.A.
48%
Associate Degree
4%
FIGURE 1
Education Distribution of New Hires  
by 2010 MLSC Tax Incentive Awardees 
Source: Dukakis Center for Urban and Regional Policy
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ies under way in university research laboratories and in 
the translational research carried out by small start-ups. 
Those few start-ups that develop potential blockbuster 
drugs or devices become prime targets for acquisition 
by the larger firms. The secret to success in the acquisi-
tion process is being where the small firms are located. 
This permits the large companies to closely monitor 
the progress of smaller firms and buy the most prom-
ising ones before “Big Pharma” competitors or other 
medical device manufacturers can make a bid. To use 
a metaphor from nature, the large, globally important 
life sciences firms want to feed in the waters where the 
minnows are swimming.  
Because Massachusetts has so many small life sciences 
firms, nine of the world’s ten major drug companies 
have now set up shop in the Commonwealth. They are 
a region becomes dominant in a particular cluster once a 
large anchor enterprise or a small number of them estab-
lish operations in that locale. Once the anchor enterprise 
is established, an array of smaller firms is attracted to that 
region to serve as part of the supply chain for the large 
anchor enterprise(s). Essentially, the small firms in the 
industry are dependent on the large ones.
For the life sciences and other highly innovative sectors, 
the reverse is true. The large companies that depend 
on the development of breakthrough innovations and 
sophisticated medical devices prosper by being near a 
concentration of small start-up firms. Even the largest 
of the life sciences companies, with substantial research 
budgets, do not have the resources to generate more 
than a handful of breakthroughs in the biosciences, 
genomics and similar fields. These big firms grow and 
prosper by carefully monitoring the scientific discover-
TABLE 2  
Economic Return on the MLSC Tax Incentive Program
Program Year 2009 Program Year 2010 Program Year 2011 3 Years of Incentives
Total Value of MLSC Tax Incentives ($) Outstanding $15,245,500 $20,672,638 $20,340,884 $56,259,022
Net New Jobs Created 901 721 915 2,537
Tax Incentive per Job ($) $22,175
Annual Tax Incentive per 5-year job ($) $4,435
Average Salary per Job ($) $105,037
Total Salaries Generated per Year ($) $266,479,399
State Income Tax Revenue per Job per year ($) $4,937
Total State Income Tax per year ($) $12,524,532
Average Sales Tax per Job ($) $2,404
Total State Sale Tax per year ($) $6,099,447
Total Income+Sales Taxes per year ($) $18,623,979
Average Income+Sales Tax/Job per year $7,341
Total Income+Sales Taxes per 5-year Job  $36,705
Total Income+Sales Taxes over 5 years $93,120,585
Tax Revenue/Incentive Ratio over 5 years                          1.66
Pharma Medical Devices Scientific Research Total
Jobs 1,843 481 213 2,537
Average Salary ($) $115,222 $66,913 $103,009 $105,037
Total Salary ($) $212,353,256 $32,185,280 $21,940,863 $266,479,399
Share of Salary 0.7969 0.1208 0.0823 1.0000
State Income Tax By Sector ($) $9,980,603 $1,512,708 $1,031,221 $12,524,532
Sales Tax by Sector ($) $4,860,554 $736,689 $502,204 $6,099,447
Source: Dukakis Center for Urban and Regional Policy
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that Big Pharma has come to swim in this pond. In 
addition, Big Pharma benefits from the Center’s invest-
ments in workforce development, shared infrastructure 
resources and cooperative research projects between 
industry and academia. The result has been extraordi-
nary output and employment growth.
The Massachusetts Life Sciences:  
A Record of Output and Employment Growth
The numbers are, indeed, impressive. As of 2012,  
according to the Massachusetts Biotechnology Council 
(MassBio), 1,198 life sciences companies were operating 
in New England and employing 103,006 workers. More 
than half of these firms are located in Massachusetts. Of 
all the Massachusetts firms listed in the 2012 MassBio 
directory, about half (514) are medical device companies; 
232 are drug development firms; 147 are contract research 
and manufacturing enterprises and 146 produce research 
products and instrumentation for the life sciences. 
The rapid growth in employment in the life sciences 
in Massachusetts provides a strong indication of how 
rapidly this sector is expanding. As Figure 2 reveals, 
the life sciences far outpaced all other industry sectors 
between 2001 and 2011.  
investing billions in plant and equipment and creat-
ing thousands of additional jobs. These include Pfizer, 
Novartis, Johnson & Johnson, GlaxoSmithKline, Sanofi 
(which absorbed Genzyme), AstraZeneca, Abbott Labo-
ratories, Merck and Bristol-Myers Squibb.
And here is the key to understanding the central role of 
the MLSC: While the large firms can easily exist without 
the MLSC’s direct investments, the small life-sciences 
ventures need the Center to provide them with accelera-
tor loans, research and development funds, and interns 
who can help them translate their ideas into commer-
cially viable products. While the private venture capi-
tal market may provide some funds for this purpose, 
venture capitalists often demand a quicker return than 
can be obtained from this sector, which often has long 
lag times between initial research, proof of concept and 
a final product approved by the U.S. Food and Drug 
Administration. 
In this environment, the MLSC has become an impor-
tant investment partner for smaller life sciences firms 
that grow out of local research universities and medical 
centers. By providing funds for translational research 
and development, the MLSC can help keep these grow-
ing companies in the Commonwealth instead of losing 
them to investment funds in other regions. To revert to 
metaphor again, it’s because these minnows stay here 
Source: BLS, Author’s Analysis
FIGURE 2
Massachusetts Employment Growth by Industry Sector 
2001–2011
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Even more impressive is the Boston-area super cluster’s 
performance relative to the United States as a whole 
and to other states vying for supremacy in this rapidly 
evolving cluster of industries. The Commonwealth 
has indeed overtaken the rest of the nation in terms of 
employment growth in the life sciences, fulfilling an 
initial goal of the MLSC. Figure 3 reveals the trend in  
life sciences employment in Massachusetts compared to 
that of the United States as a whole between 2001 and 
2011. During this period, Massachusetts life sciences 
employment growth outperformed the nation by a 
factor of better than 2-to-1—growing by 27.3 percent  
vs. 11.9 percent for the nation. 
The Commonwealth’s main competitors in the life 
sciences are California, New Jersey, New York, Florida 
and Texas. But as Figure 4 demonstrates, after 2008, the 
Commonwealth overtook all of these states in terms of 
the 2001-2011 employment growth rate. 
Moreover, when we control for population size, Massa-
chusetts is the clear winner for the entire life sciences 
cluster of industries. In Figure 5, we have controlled 
for the size of population of each state by measuring 
the number of life sciences jobs per 1 million residents. 
By 2011, given its rapid growth rate, the Massachusetts 
cluster had risen to #1 in terms of per-capita life sciences 
employment. With nearly 14,300 life sciences jobs for 
every 1 million residents, Massachusetts eclipsed all 
other states on this measure.
FIGURE 3
Employment in Life Sciences Indexed to 2001,  
Massachusetts vs. the U.S.
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FIGURE 4
Employment in Life Sciences Indexed to 2001,  
Massachusetts vs. Big Competitor States
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FIGURE 5
Life Sciences Jobs per 1 Million 2010 Population
Top 8 States in 2011, by Year
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States singled out the Massachusetts Life Sciences Tax 
Incentive Program for its focus on annual cost controls 
and its reliance on scientific merit in making awards.
Still another informant noted that the MLSC is success-
ful because its leadership is committed to working  
“at the speed of business” and therefore has become  
a valued partner in the expansion of the industry. 
Conclusions
All of our research suggests that the state will benefit 
from fully funding the remaining five years of the  
initiative in order to maintain the lead the life sciences 
super cluster has established in the Commonwealth. This 
is particularly important as other states ramp up their 
investments in hopes of creating their own life sciences 
ecosystems to entice the small and large firms Massa-
chusetts has successfully attracted. California, Maryland, 
New Jersey, New York, Minnesota and Florida are not 
resting on their laurels, but continue to spend state funds 
on their own life sciences industries.
Over time, it should be possible for the Center to reach 
out to the private sector to help fund more of its initia-
tives, as it has done with the newly established Massa-
chusetts Neuroscience Consortium. This consortium, 
established in September 2012, combines the efforts of 
the MLSC with seven global biopharmaceutical compa-
nies to jointly fund pre-clinical neuroscience research 
at Massachusetts academic and research institutions. 
Based on this model and with the plethora of larger, 
profitable firms coming to the state to expand their 
operations, one could imagine the Center funding more 
of its internships with private funds and having for-
profit companies contribute to other programs (STEM: 
science, technology, engineering and math education, 
for example), allowing the Center to focus even more of 
its resources on accelerator loans and tax incentives for 
firms undertaking translational research.
We should also note that the success of the MLSC has 
lessons for other quasi-public entities in the Common-
wealth. We can mention five of them here:
1. Long-term success in the use of tax incentives and 
business loans is most likely to occur when funds  
are focused on a cluster of firms and a set of technol-
ogies in a given industry, helping to create an indus-
trial ecosystem which can attract new companies to 
the state. 
With this growth dynamic at work, Massachusetts 
appears well positioned to continue to attract new 
investment in the life sciences super cluster. In a 2011 
analysis of the established life sciences clusters world-
wide, the commercial developer Jones Lang LaSalle 
concluded that Boston had become the #1 region for the 
life sciences. The report noted the Boston area’s concen-
tration of high-tech research and hospital/medical 
employment, its many science and engineering graduate 
students, its plentiful funding from the National Insti-
tutes of Health and venture capitalists, its investment in 
R&D as a percentage of state GDP and its research facili-
ties. Boston had a composite score of 7, ranking it #1 
overall. New York/New Jersey was #2 with a composite 
score of 24, followed by the Bay Area and Los Angeles in 
California, each with a score of 25. Boston remained #1 
in the developer’s 2012 report, while San Diego, the San 
Francisco Bay area, Raleigh-Durham, N.C., and Philadel-
phia overtook New York/New Jersey and Los Angeles.
Why Has the MLSC Been So Successful  
at Building the Life Sciences Ecosystem?
According to our interviews, the Center’s successful 
record of investments in the life sciences is grounded in 
its reliance on a Scientific Advisory Board (SAB) along 
with a large panel of experts to guide the Center’s Board 
of Directors in determining which firms show the great-
est promise. This approach to distributing public funds 
has created credibility within the super cluster and its 
ecosystem. Over and over again, we heard adjectives 
like “rigorous” and “diligent” when our informants 
described the processes MLSC uses in selecting award-
ees and providing a platform for collaboration. 
The interviews we carried out also suggested that the 
Center itself is being run quite effectively and efficiently 
and in a highly professional manner. Virtually all of our 
informants praised the management team and expressed 
special appreciation for the leadership’s refusal to permit 
political considerations to trump scientific merit. Because 
the Scientific Advisory Board (SAB) selects awardees, 
“There is not an ounce of boondoggle in this agency,” 
one informant told us. Another observed that the MLSC 
has “lots of moving parts” and all of them are working 
well. Several of the interviewees observed that the Center 
remains responsive to industry needs, meets its deadlines 
and stays focused on its mission. In its report on creating 
fiscally sound state tax incentives, the Pew Center on the 
24128_Spectrum Text.indd   11 3/14/13   11:29 AM
12 U n d e r s t a n d i n g  B o s t o n
2. The use of expert panels to determine the awarding 
of loans assures that these funds will be well utilized. 
“Claw-back” provisions protect the taxpayers by 
requiring firms to repay funds advanced by the 
Commonwealth if they fail to meet hiring goals.
3. A focus on encouraging firms in their early stage 
innovation activity is central to promoting economic 
growth and prosperity.  
4. Helping fund workforce development efforts for 
critical industries as part of the mandate of the quasi-
public entity helps ensure a pipeline of skilled work-
ers for the industry and this itself helps attract new 
firms to the region.
5. Taking a “portfolio” approach to the entire range of 
activities in the life sciences—from investments in 
small innovative firms to helping train the future 
workforce to underwriting infrastructure—helps 
sustain the “ecosystem,” undergirding a virtuous 
cycle of discovery, innovation, investment, and 
employment opportunity. 
In the end, we applaud the Governor and the Legisla-
ture for their foresight in creating the Massachusetts Life 
Sciences Center and the $1 billion Life Sciences Initia-
tive and we tip our hat to the MLSC for carrying out its 
public responsibilities in a most effective and efficient 
manner. The programs in place are fulfilling the goals 
set out in the original legislation and the Center’s lead-
ership has ensured that these programs work to the full 
benefit of the Commonwealth and its residents. 
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The Massachusetts Life Sciences Initiative, conceived by 
Governor Deval Patrick’s Administration and passed 
into law by the Massachusetts Legislature in July 2008, is 
a bold 10-year, $1 billion investment in the future of the 
state’s economy. Based on the region’s existing compara-
tive advantage in the life sciences emanating from the 
laboratories of its leading universities and medical 
institutions, this substantial infusion of public funds 
was squarely aimed at making this cluster of industry 
sectors—including biotechnology, pharmaceuticals, 
medical diagnostics, medical devices, and bioinformat-
ics—the most successful in the world. The Massachu-
setts Life Sciences Center (MLSC), founded two years 
earlier, was charged with the responsibility of imple-
menting this bold experiment in public-private sector 
collaboration. If effective, the initiative was expected to 
boost investment and jobs in this evolving industrial 
sector, generating increased household income and tax 
revenue for the state.
In 2012, at the near halfway point of that 10-year initia-
tive, the Dukakis Center for Urban and Regional Policy 
at Northeastern University was invited by the MLSC 
to measure the progress of the life sciences sector in 
Massachusetts and to carry out an evaluation of the 
Center’s activities. We agreed to conduct such a study, 
but only under the condition that we would have full 
access to MLSC records, that our investigation would 
not be censored in any way by the MLSC staff, and that 
the staff of the Dukakis Center would have absolute 
control over the content of the final evaluation report. 
As a result, this report is being published by the Boston 
Foundation as part of its Understanding Boston series.
For the past year, Barry Bluestone, Director, and Alan 
Clayton-Matthews, Senior Research Associate at the 
Northeastern center, have carried out this evalua-
tion. Both of us are economists who have extensive 
experience in industry studies and in program evalua-
tion. Neither of us, however, was an expert on the life 
sciences sector when this evaluation project was  
first launched. 
Introduction
In the course of this research, we immersed ourselves 
in literature about the components of the life sciences 
industry cluster and about the role of public invest-
ment in innovation and economic growth. We analyzed 
existing employment data on each of the life sciences 
industries in the state; reviewed all of the annual reports 
of the MLSC; attended meetings of the MLSC Board 
of Directors where decisions over tax incentives and 
awards were made; and conducted lengthy interviews 
with leading executives of life sciences companies 
located in the state, industry trade association leaders, 
and members of the MLSC Scientific Advisory Board. 
This report is based on all of the data gathered over  
the year.
We began this research fully agnostic about what we 
might ultimately find, given the checkered record across 
the country of state industrial policy aimed at assist-
ing other industries. But what we have found, based on 
our research, is that the Commonwealth’s life sciences 
initiative is meeting, if not exceeding, the goals first 
established in 2008 by the Governor and the Legislature. 
Moreover, our interviews with key informants led us 
to the conclusion that the Massachusetts Life Sciences 
Center is executing its responsibilities in an effective, 
efficient, and professional manner. The initiative and the 
MLSC has performed exceptionally well in creating an 
ecosystem within which the cluster has prospered. 
Moreover, we have concluded that the Center’s mission, 
administration, and performance provide important 
lessons that can be applied to other state agencies 
charged with encouraging economic development.
This research could not have been carried out without 
the assistance of the staff of the MLSC and the many 
industry executives and experts who provided us with 
data and candid answers to our probing questions. We 
thank them all for their time and the information they 
afforded us.
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CHAPTER ONE
About the Massachusetts Life Sciences Center
growth. This has diminished tax revenue just when 
the swelling cost of health care and public pensions is 
generating structural deficits.3 Without additional tax 
revenue from more vigorous growth, these potential 
deficits will require either raising taxes or cutting public 
services, or both. 
In this new economic environment, virtually every  
unit of government is being forced to husband its 
resources and scrutinize its spending to assure that every 
tax dollar is spent effectively and efficiently. As such, it is 
not surprising that the nation, the Commonwealth, and 
most of its municipalities are considering ways to cut 
“unnecessary” or “wasteful” spending. At the same time, 
they want to preserve essential public programs that meet 
critical social needs and improve the targeting of incen-
tives to the private sector to accelerate economic growth. 
A prime target in this new era of public scrutiny is the 
extensive set of “subsidies” and “tax expenditures” 
that governments have traditionally used to encourage 
specific types of consumption or investment. Every tax 
dollar that a government agency transfers to a private 
business or individual in the form of a subsidy means a 
dollar less that can be used in the short-term for other 
purposes. Every dollar that a business or individual 
saves on its taxes is an “uncollected” dollar—a tax 
expenditure—that could have been used to pay for one or 
another public service.4 Because of the short-run “oppor-
tunity costs” attached to every dollar spent, there is a 
growing demand to ensure that public dollars are not 
being wasted on programs that have little payoff. Each 
program must be judged on whether the long-term gain 
from issuing a tax incentive, government grant, loan 
guarantee, or subsidy outweighs the short-term cost to 
the treasury.
Adding to the demand for more accountability has been 
a recent series of high-profile cases of “failed” govern-
ment incentive programs. Solyndra, a manufacturer of 
solar photovoltaic systems, became the poster child for 
“misspent” federal funds during the last presidential 
campaign when it filed for bankruptcy after receiving 
In June 2006, the Massachusetts Legislature created 
a new quasi-public agency, the Massachusetts Life 
Sciences Center (MLSC), to promote the life sciences 
within the Commonwealth. It was tasked with “invest-
ing in life sciences research and economic develop-
ment . . . by making financial investments in public 
and private institutions.”1 Its mandate was broad: to 
encourage basic research, development, and commer-
cialization in the biosciences; ensure the preparation of a 
skilled workforce to meet the needs of the state’s biosci-
ence industry cluster, and build stronger collaboration 
between the sectors of the local and international life 
sciences community.2
A year later, in May 2007, Governor Deval Patrick 
revealed an ambitious plan for a 10-year, $1 billion 
public initiative to enhance the Commonwealth’s exist-
ing competitive advantage in this rapidly evolving and 
critically important sector of the U.S. economy. This 
would provide the funding for a major expansion in 
the activities of the Life Sciences Center. In June 2008, 
the legislature enacted the Governor’s Massachusetts 
Life Sciences Initiative with the aspiration of building 
on the existing strengths of the state’s research univer-
sities, its world-renowned health care sector, and its 
emerging private sector life sciences firms to promote 
the Commonwealth as the foremost center for the life 
sciences in the world.
With such a large commitment of state resources, how close 
has the Center come to meeting this goal? Has it helped 
attract life sciences companies to the Commonwealth, boosted 
R&D in the private life sciences arena, created job opportu-
nities for Massachusetts workers and increased the state’s 
revenue base by boosting employment, household income, and 
corporate profits? 
This analysis of the MLSC comes at a propitious time. 
Massachusetts, along with most of its cities and towns—
not to mention the nation as a whole—faces growing 
fiscal constraints. The economic recession that officially 
began in late 2007 and officially ended in 2009 has 
given way to an extended period of sluggish economic 
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stances should states use tax abatements, subsidies, and 
other inducements to encourage investment and create 
jobs in the private sector?7 
As the Massachusetts Life Sciences Initiative approaches 
the halfway mark in its 10-year legislative life, it is alto-
gether appropriate that this report attempt to ascertain 
whether, and to what extent, the Massachusetts Life 
Sciences Initiative has already produced tangible positive 
gains for the Commonwealth, and whether maintaining 
the initiative will likely produce even greater long-term 
benefits for the state’s residents and taxpayers. 
For the purposes of this report, we define the Life 
Sciences cluster as consisting of sixteen (16) specific 
6-digit NAICS industry sectors as shown in Table 1.8 
These include two research and development industries, 
two laboratory industries, two medical distribution 
$535 million in U.S. Energy Department loan guaran-
tees.5 The same was true when A123, a manufacturer 
of lithium ion batteries for electric cars, went bankrupt 
after receiving a $130 million federal grant to build 
a plant in Michigan. It was, according to a series of 
Washington Post reports, the fifth clean-energy firm the 
current Washington administration subsidized with 
loans or grants that filed for bankruptcy protection. 
During the campaign, Republicans claimed both Solyn-
dra and A123 were prime examples of “cronyism” in 
President Obama’s stimulus program.6
Closer to home was the failure of Curt Shilling’s 38 
Studios video-game firm. It closed its doors and laid 
off all of its employees after Rhode Island lured it from 
Massachusetts with a $75 million loan guarantee. This 
case raised anew an old question. Under what circum-
TABLE 1 
Life Sciences Sectors 
Group NAICS Title
1 325411 Medicinal and Botanical Manufacturing
1 325412 Pharmaceutical Preparation Manufacturing
1 325413 In-Vitro Diagnostic Substance Manufacturing
1 325414 Biological Product (except Diagnostic) Manufacturing
2 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing
2 334516 Analytical Laboratory Instrument Manufacturing
2 334517 Irradiation Apparatus Manufacturing
3 339112 Surgical and Medical Instrument Manufacturing
3 339113 Surgical Appliance and Supplies Manufacturing
3 339114 Dental Equipment and Supplies Manufacturing
4 423450 Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
4 424210 Drugs and Druggists’ Sundries Merchant Wholesalers
5 541711 Research and Development in Biotechnology
5 541712 Research and Development in Physical, Engineering, and Life Sciences (except Biotechnology)
6 541380 Testing Laboratories
6 621511 Medical Laboratories
Source: Battelle and the Biotechnology Industry Organization (June 2012)
24128_Spectrum Text.indd   16 3/14/13   11:29 AM
17L i f e  S c i e n c e s  I n n o v a t i o n  a s  a  C a t a l y s t  f o r  E c o n o m i c  D e v e l o p m e n t
sectors, and ten different manufacturing industries.9 
The cluster also includes the life sciences depart-
ments in universities and medical institutions in the 
Commonwealth.10
As of 2012, according to the Massachusetts Biotechnol-
ogy Council (MassBio), there were 1,198 life sciences 
companies operating in New England employing 
103,006 workers, the vast majority of these firms located 
in Massachusetts. More than one-third of these New 
England firms were founded after 2004 and 80 percent 
are relatively small with sales under $100 million a year. 
More than two out of five of these firms (43%) have 
annual sales of less than $5 million. Of all the Massachu-
setts firms listed in the 2012 MassBio directory, about 
half (514) are medical device companies; 232 are drug 
development firms; 147 are contract research and manu-
facturing enterprises; and 146 produce research prod-
ucts and instrumentation for the life sciences.11 
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percent of the state budget or $345 per capita. Of this 
total, more than a third ($786 million) take the form of 
corporation income tax credits, rebates, or reductions. 
Another $130 million is paid out by the state treasury in 
the form of cash grants, loans, or loan guarantees. 
The Times reporters listed a group of 94 Massachusetts 
companies that received nearly $165 million in grants, 
tax incentives, and subsidies between 1994 and 2011. 
Of this total, 26 were life sciences companies account-
ing for $48.7 million or nearly 30 percent of the total. 
Among the companies receiving these funds were 
Vertex Pharmaceuticals, Organogenesis, Shire Human 
Genetics Therapies, Sanofi, and Cubist Pharmaceuti-
cals. The company receiving the largest state subsidy, 
however, was Liberty Mutual, an insurance company. 
Between 2006 and 2009 alone, the Massachusetts Film 
Office doled out nearly $150 million in tax credits to 
film companies.17
States like Alaska, West Virginia, Texas, and Michigan 
spend two to three times as much per capita as Massa-
chusetts on such business incentives, but other states 
including New Hampshire ($30), North Carolina ($69), 
California ($112), South Carolina ($194), New York 
($210), Florida ($212), Oregon ($226), Connecticut ($241), 
and Ohio ($281) spend less.
Obviously, in a time of tight fiscal budgets, such expen-
ditures of tax revenue need to be carefully evaluated 
as elements of what is known as “industrial policy”— 
government support of private business. 
To assure that this assessment of the Massachusetts Life 
Sciences Center is placed in proper context, we need to begin 
by considering the ways in which government can encourage 
private sector economic development in an efficient and effec-
tive way. In doing this, we need to pay particular attention to 
understanding the role of government-induced innovation in 
spurring economic growth.This foray into these theoretical 
issues will provide us with guidance as to what types 
of government tax expenditures and subsidies are more 
likely to yield positive benefits for society and thereby 
help us to assess the value of the MLSC.
CHAPTER TWO
The Size and Scope of Public Tax Expenditures  
and Public Subsidies
To begin our assessment, it is useful to put the Common-
wealth’s $1 billion investment in the life sciences into 
perspective. According to the Congressional Research 
Service, at the federal level there are over 200 separate tax 
expenditures which taken altogether are projected to cost 
the U.S. Treasury more than $1.1 trillion in FY2014.12 The 
bulk of these take the form of exemptions, deductions, 
and exclusions from the personal income tax such as the 
mortgage interest deduction. These tax provisions are 
intended to encourage such “virtuous” behavior as home 
ownership, charitable contributions, and family saving.13 
While paling in comparison to these personal tax  
expenditures, federal corporate subsidies cost the Treas- 
ury almost $100 billion a year, according to research 
conducted by the Cato Institute.14 A full quarter of these 
go to farmers in the form of agricultural subsidies and 
crop insurance, but other subsidies underwrite applied 
research and development under way at defense contrac-
tors, energy companies, housing developers, airlines, 
AMTRAK, universities and research labs, the National 
Institutes of Health, NASA, and small businesses.15 In 
searching for ways in 2013 to cut federal spending in 
order to reduce federal deficits, one can be certain that 
some, if not many, of these tax expenditures and subsidies 
will be reviewed for possible modification or elimination.
States and municipalities have also provided the private 
sector with billions in tax expenditures and subsidies. In 
a recent series of articles, a trio of New York Times inves-
tigative reporters found that across the nation, states, 
counties, and cities dole out over $80 billion in “business 
incentives” each year.16 The key industries receiving such 
tax preferences and subsidies are manufacturing; agri-
culture; the oil, gas, and mining industries; and the film 
industry. Technology companies like Twitter and Face-
book, according to the Times report, are not far behind.
The Times analysts collected data on all 50 states. In 
their review of Massachusetts, they found 48 state 
programs that provide nearly 1,500 grants or incentive 
packages to specific companies. The total annual cost 
to state and municipal governments for these programs 
was reported to be at least $2.26 billion, equal to seven 
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CHAPTER THREE
Industrial Policy: Pros and Cons
private businesses bring these innovations to the stage 
where they can be effective in the marketplace.”21 In 
brief, well-placed public funds in the private sector can 
yield large long-term gains at relatively modest short-
term cost.
But what makes for “well-placed” public funds? A good 
part of the answer lies in whether the funds contrib-
ute significantly to a growing economy and increasing 
numbers of jobs. 
New vs. Old Growth Theory
In economics, there are two fundamentally different 
views about what contributes most to growth. What is 
now known as the “old growth theory” suggested that 
economic prosperity emanates from the accumulation 
of ever greater stocks of the fundamental ingredients 
of production: capital, labor, and natural resources. 
Those countries that find ways of increasing investment 
in plant and equipment, adding to labor supply, and 
extracting more natural resources are the ones that will 
become more affluent. Just consider the United States or 
Saudi Arabia versus poor countries in Africa or South-
east Asia. Clearly, without capital, labor, and natural 
resources, output cannot be produced.
While not completely discounting this approach to 
growth, a “new growth theory” has evolved that “places 
technological progress at the very epicenter of growth 
dynamics, rather than capital investment per se.”22 
Advances in technology and interdependencies between 
new ideas and new investment provide the basis for 
entire new industries and products that create new 
wealth and raise living standards. “In the new model, 
technology provides the engine for sustained growth in 
the face of the diminishing productivity associated with 
additions to the stock of physical and human capital.”23 
In addition to avoiding diminishing returns, innovation-
based growth has an additional salutary feature relative 
to other ingredients in the growth equation: Once the 
fixed cost of creating a technology has been incurred, 
For decades, economists have debated the role of govern-
ment in the promotion of private industry. At various 
times in our history, the federal government has helped 
to establish industries that went on to be central to our 
economy. The growth of the nation’s aircraft industry was 
aided by the U.S. Post Office, which subsidized airlines 
with lucrative air-mail contracts in the early days of air 
travel. In the aftermath of Sputnik, the federal govern-
ment invested billions of research dollars into perfecting 
solid state guidance systems and software for rockets and 
missiles, helping to create what today is our high-tech 
universe of cell phones, the Internet, iPads, GPS devices, 
and a dizzying array of gadgets based on the integrated 
circuit and the software that runs them. 
Yet, as a recent Center for Economic and Policy Research 
working paper put it, “For the past generation, the 
dominant view among economists was that giving busi-
nesses a free hand—that is, little regulation and low 
taxes—was the most important contribution govern-
ments could make to encourage productive investments. 
The corollary to this view was that, as much as possible, 
overall investments in the economy should be under-
taken by the private sector, as opposed to any sort of 
government entity.”18 
The argument against a public “industrial policy” is that 
governments are not capable of “picking winners” and 
therefore too often waste tax dollars. The conservative 
Cato Institute claims that government subsidies inevi-
tably distort economic activity and “create even larger 
failures than might have existed in the marketplace.”19 
By aiding some businesses, others are placed at a disad-
vantage either by reason of having to pay higher taxes or 
having to compete with subsidized firms. Hence, divert-
ing resources from businesses preferred by the market to 
those preferred by policy makers leads to losses for the 
overall economy.”20
The argument for public investment in the private sector 
is that rather than “crowding out” private capital, public 
investments actually “crowd in” private investment and 
can be used to “incubate new technologies and help 
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but it was not until the 1990s that the full productivity 
premium of the computer generation was finally real-
ized.28 It will take decades to realize the full benefits 
to humanity and the economy from the advances now 
being made in drug discovery, medical diagnostics, and 
medical devices.
Unfortunately, in an era of intense concern over short-
term deficits, it is often hard to marshall the patience 
needed to invest sufficiently in technological innovation 
or the firms that create it. As a corollary, investments 
made today in research and development (R&D) are 
often risky propositions from the perspective of the 
short-term balance sheet. Yet without massive infusions 
in R&D, continuous breakthrough innovation cannot 
occur. Nowhere is this truer than in the life sciences.
Public Investment in R&D
Worldwide, no country spends more than the United 
States on R&D, and this investment has played an impor-
tant role in the nation’s economic development, at least 
since World War II.29 According to the Battelle Institute, 
total R&D spending in the U.S. reached $436 billion 
in 2012, of which about 29 percent ($126 billion) was 
supplied by the federal government while 64 percent 
($280 billion) was provided by private industry. The 
remainder came from foundations and other non-profits 
($14.5 billion), university-owned funds ($12.3 billion), 
and a tiny amount from state and local governments ($3.8 
billion).30 
Despite its smaller share of overall R&D funding rela-
tive to the private sector, the importance of the federal 
government in spurring innovation should not be under-
estimated. Without government investment, it is likely 
that private firms would underinvest in R&D, particu-
larly basic research. The reason is that the social rate of 
return to investment in basic research often exceeds the 
private rate. Unlike investments in tangible capital such 
as machinery, the ideas flowing from R&D are, in the 
words of economists, “nonrival” and not fully “appropri-
able.” Nonrival means that my learning of a new innova-
tion does not prevent you from using it. When returns 
are not fully appropriable, the original innovator cannot 
gain all the profit that flows from the eventual applica-
tion, especially the commercialization, of the new process 
or product.31 In this case, firms will often wait for others 
to do the innovating. As Federal Reserve Bank Chair-
the formula can be used over and over again at little or 
no cost. Indeed, this spillover property is taken to be the 
defining characteristic of technology. As Paul Romer, 
one of the founders of new growth theory puts it, “The 
idea behind the transistor, the principles behind internal 
combustion, the organizational structure of the modern 
corporation, the concepts of double-entry bookkeep-
ing—all these pieces of information and many more like 
them have the property that it is technologically possible 
for everybody and every firm to make use of them at the 
same time without additional costs.”24 As such, instead 
of diminishing returns to investment, there can be 
increasing returns. 
Moreover, the new growth theory posits a strong reci-
procity between the rate of skill acquisition among 
workers and the growth dividend society obtains from 
new capital and new inventions. Thus, programs that 
combine incentives for innovation along with resources to 
augment human capital should, according to this theory, fuel 
rapid economic growth more than anything else society can do 
to promote prosperity. 
But here is the rub. Keeping score on the success of  
innovation is difficult. Instead of a more or less certain 
return to a given infusion of capital under the old 
growth theory, innovation under the new growth 
theory tends to deliver faster and stronger long-term 
growth, but it is “lumpy, discontinuous, and nonlin-
ear.”25 There can be long lags between the time a new 
innovation is first incorporated into production and 
the time that it pays off in terms of increased produc-
tivity, output, and jobs. The introduction of the steam 
engine in the mid-18th century did not pay off in terms 
of improved productivity until the early 19th century.26 
In the short term, it can be discouraging, as invest-
ments in fundamental innovation usually have little 
immediate payoff.
To be productive, innovation needs to be perfected and 
diffused, and this takes time. According to a study of 
265 major and minor innovations over the past couple 
of centuries, it took a typical new innovation forty-one 
years, on average, to move from the 10 percent to the 
90 percent diffusion level.27 The diesel locomotive, for 
example, was clearly superior to the steam locomotive, 
yet twenty years after the first diesel was introduced in 
1925, there were still nearly ten steam locomotives in 
service for every diesel-powered engine. The first inte-
grated computer circuits were introduced in the 1960s, 
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over $140 billion by 2009. In FY 2013, under pressure  
to reduce federal spending, total federal R&D spending 
once again declined.34 
As Figure 2 demonstrates, virtually all of this growth 
in non-defense federal R&D spending has been in the 
health field, mainly through the National Institutes of 
Health. While federally sponsored health research only 
accounted for about seven percent of total non-defense 
federal R&D spending in 1965, by 2013 it accounted for 
more than half (52%). Much of this basic public invest-
ment is going into the life sciences, and of all fifty states, 
Massachusetts trails only California in NIH funding. In 
2011, California institutions received $3.5 billion in NIH 
funding; those in Massachusetts received $2.5 billion.35 
Yet, on a per capita basis, the Commonwealth swamps 
all other states in NIH funding, obtaining four times as 
much as the Golden State.
This growth in federally sponsored R&D seems impres-
sive, but as a share of the nation’s Gross Domestic Prod-
uct (GDP), the federal government’s role is roughly half 
of what it was in the early 1960s (see Figure 3). Spending 
rose rapidly in the 1950s and 1960s, surpassing  
1.9 percent of GDP in 1964, up from just 0.7 percent in the 
early 1950s.36 Much of this was in direct response to the 
Soviet Union’s launching of Sputnik and President John 
F. Kennedy’s goal of sending a man to the moon before 
1970. After reaching its nadir of just 0.67 percent in 2000, 
it has slowly climbed back to 0.85 percent today.37
man Ben Bernanke recently reminded an audience at a 
Washington, D.C. conference, “James Watson and Francis 
Crick received a minute fraction of the economic benefits 
that have followed from their discovery of the structure of 
DNA.”32 Without government-sponsored basic research, 
society loses out on innovation. 
Public sector R&D also encourages private sector R&D 
spending. Research reveals that there is a strong posi-
tive correlation between the trajectory of private R&D 
spending in a given year following public expenditures 
a year earlier.33
The Trend in Federal R&D Spending
Given (1) the importance of innovation as the prime 
driver of economic prosperity, (2) the role of R&D in 
promoting innovation, and (3) the fact that without 
public funding of R&D total research investment would 
be suboptimal because of the inability of private inves-
tors to fully appropriate its monetary benefit, how much 
has the federal government invested in this vital factor?
As Figure 1 reveals, federal spending on defense and 
nondefense R&D (in inflation-adjusted FY2012 dollars) 
rose sharply between 1953 and 1965 from less than  
$15 billion to more than $80 billion before dipping back 
to just over $60 billion in 1976. Spending was back 
to more than $100 billion by 1989 and remained flat 
through 2001. It rose sharply after that, increasing to 
Source: American Association for the Advancement of Science
FIGURE 1
Federal Spending on Defense and Nondefense R&D
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cluster. Such locational advantages are called agglomera-
tion economies and refer to the benefits, savings, or cost 
reductions resulting from the clustering of economic 
activities.38 The clustering of such industries can give 
rise to an “industrial climate” or “ecosystem” that is 
self-perpetuating as the result of a regional congregation 
of specialized facilities, labor pools, education and train-
ing institutions, and specialized legal, accounting, and 
financial services. 
Such agglomeration economies explain the economic 
success of most metropolitan areas. In New York City, 
for example, the cluster of financial industries and 
advertising is responsible for much of the growth in 
wealth. The birth of the early auto industry in and 
around Detroit in the early part of the 20th century 
would ultimately allow Detroit to take advantage of 
agglomeration economies and blossom into the world’s 
“Motor City” by the end of World War II. By 1949, the 
median family income of Detroiters was higher than 
that of any other city in America except Chicago (whose 
residents enjoyed a 1949 median family income exactly 
one dollar higher), and 29 percent above the national 
figure.39 Chicago’s prosperity was built on being the 
transportation hub for America. Seattle became the 
center for jet aircraft production. 
In the postwar period, the most successful new indus-
As we have seen, new growth theory suggests that our 
nation’s prosperity is intimately tied to the rate of innova-
tive activity. If innovation slows down, growth will suffer. 
Hence, the big question is whether the United States can 
maintain its rate of innovation activity into the future and 
thereby sustain economic prosperity and full employment.
The Role of R&D Investment  
at the State Level
As noted above, states have historically played a minor 
role in funding research and development. Their $3.8 
billion spent in FY2012 amounted to less than 1 percent 
of total spending on R&D and no more than 3 percent of 
government-sponsored R&D. Indeed, given that the full 
benefits from basic research cannot be easily appropri-
ated by the funder, it might seem foolish that an individ-
ual state would spend its own revenue on investments 
that can be appropriated by entities in other states.
So why should a state invest anything in R&D?
Invested in the appropriate industries, public funds 
can help encourage the growth of an industrial cluster 
in a given region that, once incubated, can maintain 
a self-sustaining locational advantage that provides 
a magnet for new private investment in the region’s 
Source: American Association for the Advancement of Science
FIGURE 2
Trends in Nondefense R&D by Function, FY 1953–2013
Outlays for the conduct of R&D, billions of constant FY 2012 dollars
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significant fraction of all research funds in the comput-
ing field, particularly underwriting academic research. 
Federal support has constituted roughly 70 percent of 
total university research funding in computer science 
and electrical engineering since 1976.”42 
The lesson is that the prosperity of many metropolitan areas 
has been stimulated in large measure by public investments in 
particular industry clusters. Given an early start in an indus-
try, public funds can help build the agglomeration economies 
that in turn cement a single region’s leadership in that indus-
try nationally and globally. The Massachusetts Life Sciences 
Center was established precisely to this end. How successful 
has it been?
trial cluster was built in Silicon Valley in and around 
Palo Alto, California. Beginning in 1939 with the found-
ing of Hewlett-Packard— the brainchild of two Stanford 
graduate students—the valley would attract a host of 
firms that would ultimately build the modern computer 
industry and make this region one of the wealthiest in 
the world.40 
In the case of Detroit, local, state, and the federal 
governments essentially subsidized the auto industry 
through the public provision of streets, roads, and high-
ways. Chicago’s prosperity was underwritten by public 
subsidies to the railroads. Seattle’s aircraft industry has 
benefited not only from the early airmail contracts but 
from massive defense spending that provided most 
of the resources needed to develop both military and 
then commercial jet airframes and jet engines.41 While 
private venture capital has played a major role in the 
success of Silicon Valley, the federal government has 
played a significant role as well. From less than $10 
million in 1960, federal research funding of computer 
science climbed to almost $1 billion by 1995, while the 
U.S. expenditure on research in electrical engineering 
(which includes semiconductor and communications 
technologies) has fluctuated between $800 million and 
$1 billion since the 1970s. According to the National 
Research Council, such funding “has constituted a 
Source: National Science Foundation “Science and Engineering Indicators 2012”
FIGURE 3
Federal Spending on R&D as Percent of GDP 
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CHAPTER FOUR
The Emergence of the Massachusetts  
Biotechnology Super Cluster
(SBIR) to support basic research; foundation support 
from private nonprofits; and, on the for-profit side, 
angel and venture capital (VC) investors who provide 
funds for translating basic research into new products 
and services. The cluster is also supported by public and 
private customers for its end products, which at times 
are subsidized through tax expenditures and subsidies.
The talent pool for this sector ranges from creators and 
craftspeople who play the role of principal investiga-
tors on research grants and contracts, entrepreneurs 
who form new firms to commercialize the output of the 
sector and workers who range from those with just a 
high school diploma to those with Ph.Ds.
To be successful, the cluster must also enjoy a legal 
system that protects intellectual property through 
patents and licenses and IP enforcement in the courts.
Long-term success for the cluster also requires a diverse 
set of “tradable agglomerating” companies comprised 
of new innovative enterprises that can power future 
In 2010, four scholars at the Massachusetts Institute of 
Technology (MIT) developed a schematic to explore the 
complement of elements needed to produce a success-
ful American biotechnology cluster.43 This schematic is 
summed up in Table 2. The schematic includes three 
innovation stages and four critical factors. Based on this 
matrix, the team was able to describe all of the aspects  
of what they called the Massachusetts Biotechnology 
Super Cluster.
A thriving science-based cluster must take basic research 
and transition it into commercial products and services. 
To do this requires funding, skilled labor, a legal frame-
work that protects intellectual property (IP), and a diverse 
set of industries that includes both new innovative firms 
as well as established ones. As the authors suggest, “inad-
equacies in any area can threaten the cluster.”44
As a whole, the U.S. biotechnology cluster benefits from 
access to both public and private sources of funding. 
These include, on the public side, NIH, the Department 
of Defense (DOD), Small Business Innovation Rewards 
TABLE 2
The Prototypical American Biotechnology Cluster
Critical Factors
Innovation Stages
Basic Research Translation Commercialization
 Funding
Public NIH DOD, SBIR Payers, Tax Policy
Private Foundations Angel, VC, Industry Customers
Talent
Creators PIs Entrepreneurs Senior Execs
Craftspeople Grad Students BA/MS/PhD HS - PhD
 Laws & Norms
Intellectual Property Bayh-Dole Patentability & Scope IP Enforcement
Experimentation New Field Encouragement
Independence 
Over Security Reinvention
Diversity
Tradable Agglomerating Stem Cells RNA, Interventional Imaging Biologics
Tradable Converging Bio-processing Molecular Diagnostics Biomanufacturing
Local Sustaining Medical Centers Science Parks
Source: Trusheim, Berndt, Murray, and Stern, 2010
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pharmaceutical giant, Roche—the world’s third-largest 
biopharma firm—has not moved into Massachusetts.46
According to a separate comprehensive analysis of 
the global life sciences cluster completed in 2011, the 
commercial developer Jones Lang LaSalle concluded 
that Boston had become the #1 region for the biosciences 
based on its concentration of high tech research and 
hospital/medical employment, its number of scientific 
and engineering graduate students, its level of NIH 
and venture-capital funding, its investment in R&D as 
a percentage of state GDP, and its thousands of square 
feet of academic and research institute facilities. Boston 
had a composite score of 7 ranking it #1 overall. New 
York/New Jersey was #2 with a composite score of 24, 
followed by the Bay Area and Los Angeles each with a 
score of 25.47 
growth through the development of breakthrough prod-
ucts, “tradable converging” firms which remain glob-
ally competitive in existing products, and a set of local 
entities including medical centers and science parks that 
provide local services to the cluster.
A good deal of this requires a collaborative form of 
industrial policy with both the federal and state govern-
ment playing major roles in the emergence of the cluster. 
In the 1950s, the federal government continued its fund-
ing of R&D in the biosciences as part of its Cold War 
strategy. The VC model was invented and the first high-
tech firms founded. In the 1970s, the federal government 
declared a “War on Cancer” with NIH funding, while the 
first recombinant DNA experiments were undertaken in 
university laboratories and private research firms. 
In 1980, the Bayh-Dole Act was adopted, giving univer-
sities IP ownership of the output from federally funded 
research while the first recombinant DNA products hit 
the market. In the Commonwealth, the Massachusetts 
Biotechnology Council was created in 1985, one of 
the first in the nation. In the 1990s, the first genomics 
companies were founded, led initially by Millennium 
Pharmaceuticals (established by a former Genentech 
executive). 
Much of this early work came to fruition in the first 
decade of the 21st Century. During this period, the 
human genome was sequenced and the George W. 
Bush administration committed itself to doubling 
the NIH budget. 
Here in the Commonwealth, a final piece of the cluster 
puzzle was put in place with the founding of the MLSC, 
followed by the state’s funding of the Life Sciences 
Initiative to help cement the region’s lead in this impor-
tant cluster and maintain that lead into the future. With 
all of the other parts of the matrix in place in Massachu-
setts, the state became a magnet for Big Pharma. 
By the end of the first decade of the 21st Century, Massa-
chusetts was home to 9 of the top 10 major drug compa-
nies in America, surpassing New Jersey. Pfizer, Novartis, 
GlaxoSmithKline, Genzyme’s successor Sanofi, Astra-
Zeneca, Abbot Laboratories, Merck and Bristol-Myers 
Squibb had all committed to operations in the Bay State. 
The largest of these big firms, in order of employment, 
are Genzyme (Sanofi), Pfizer, Biogen Idec, Novartis, 
Shire, Thermo Fisher Scientific, EMD Millipore, Vertex, 
Parexel International, and Hologic.45 Only the Swiss 
24128_Spectrum Text.indd   28 3/14/13   11:29 AM
29L i f e  S c i e n c e s  I n n o v a t i o n  a s  a  C a t a l y s t  f o r  E c o n o m i c  D e v e l o p m e n t
CHAPTER FIVE
The Massachusetts Life Sciences Center
Life Sciences Accelerator Program—Provides financ-
ing of up to $1 million for early-stage companies to help 
leverage additional sources of capital.
Small Business Matching Grant (SBMG) Program—
Provides matching support capped at $500,000 per 
company to firms on the verge of commercializing new 
technologies developed using Phase II or Post-Phase II 
Small Business Innovation Research (SBIR) awards or 
Small Business Technology Transfer (STTR) grants from 
the federal government.
Life Sciences Tax-Incentive Program—Issues a combi-
nation of 10 competitively awarded tax incentives 
available to companies that meet specified hiring goals. 
These include:
n A refundable 10% investment tax credit49
n A refundable in-state research tax credit
n A refundable job creation tax credit (50+ jobs)
n A refundable FDA user fee credit
n Extension of net operating losses to 15 years
n Deduction of orphan drug clinical testing
n Elimination of the sales factor throwback provision
n Special sales tax exemption
n Life sciences research credit for out-of-state costs
n Construction sales tax exemption
Capital Projects Fund—Provides capital for equipment 
and supplies for high schools in Gateway Cities,  
vocational/technical schools, and community colleges; 
and for capital projects in academic/research institu-
tions, business incubators, and other not-for-profit  
organizations in the Commonwealth.
Between 2008 and June 30, 2012, the Center had directly 
invested or committed over $300 million that has lever-
aged more than $1 billion in third-party investment, 
according to the MLSC’s report for fiscal year 2012. 
If none of that investment would have been made in 
Massachusetts in the absence of the MLSC commit-
What role does the MLSC play in the MIT schematic? 
Beginning with its creation, the MLSC took as its stra-
tegic mission the role of pulling together all of the parts 
of the matrix into a life sciences ecosystem, creating a 
dense, highly connected community of scholars, entre-
preneurs, industry leaders, venture capitalists, and 
government officials dedicated to the success of the life 
sciences super cluster in the Commonwealth. Unlike 
many state economic development initiatives, the 
Center has a broad range of strategic priorities geared 
to enhance all aspects of the life sciences cluster. These 
include:
n funding translational research—research that 
converts basic research into marketable products and 
services
n investing in promising new technologies
n ensuring worker skill acquisition that aligns with the 
needs of the life sciences industries
n creating new infrastructure from shared resources 
that accelerates innovation
n building partnerships between sectors of the local 
and international life sciences communities
To accomplish these goals, the Center relies on a portfo-
lio of seven distinct programs.48 These include:
Cooperative Research Grants—Supports industry-
sponsored research at universities and facilitates scien-
tific discoveries that lead to medical applications. These 
grants of $250,000 per year for up to two years match 
industry contributions dollar for dollar.
Internship Challenge Program—Provides up to $7,200 
in funds for interns working at Massachusetts compa-
nies with fewer than 100 employees and fewer than  
250 globally.
New Investigator Grants—Spurs innovative research 
and advances the careers of new investigators who are 
working on cutting-edge research at Massachusetts 
academic research centers with grants of $100,000 per 
year for up to three years.
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Examples of infrastructure activity as listed in MLSC’s 
FY2012 report include:
n $5 million in support of the construction of the Joslin 
Center’s Translational Center for the Cure of Diabetes
n $10 million to the Dana Farber Cancer Institute to 
support the expansion of its $20 million Molecular 
Cancer Imaging Facility
n $5 million to the Boston Museum of Science for the 
construction of its “Hall of Human Life,” which 
helped leverage $11 million in private financing
n $14.6 million to the University of Massachusetts Dart-
mouth to build its new Massachusetts Biomanufac-
turing Center in Fall River
n $10 million to UMass Lowell to equip laboratories 
within its new Emerging Technologies and Innova-
tion Center
n $14.3 million to help build the Framingham Waste-
water and Pumping Station that will allow bioscience 
firms to operate in that community
Examples of accelerator loans awarded in FY2012 to 
provide working capital to early stage life sciences 
companies include:
n $750,000 to Allurion of Wellesley for developing a 
novel medical device for inducing weight loss in 
obese patients
n $750,000 to Alcyone Lifesciences, Inc. for the devel-
opment of a micro-catheter for treating neurological 
conditions
n $245,000 to Strohl Medical for the creation of a medi-
cal device for accelerating the treatment of stroke 
victims
Subsequent to receiving accelerator loans, early stage 
firm recipients have raised more than $100 million in 
either private or public funding to grow their firms or 
in acquisition proceeds. Already six firms that have 
received accelerator loans have paid them off early, 
permitting the MLSC to construct a revolving fund, thus 
expanding the resources the Center has for this purpose.
In addition to the accelerator loans, the MLSC has begun 
a Small Business Matching Grant Program (SBMG), 
which complements funds received by firms from NIH, 
the National Science Foundation (NSF), and DOD. In 
2012, the Center awarded a $500,000 grant to Firefly 
BioWorks, Inc. of Cambridge after full review by the 
ments, each dollar of taxpayer money spent by the 
Center resulted in the attraction of $3.40 in additional, 
outside investment creating a public-private investment 
fund of more than $1.3 billion.50
There are four factors that make the MLSC quite differ-
ent from most government subsidy programs:
n Instead of simply providing tax benefits to a few 
private firms to lure them to the Commonwealth, the 
MLSC has a portfolio of investment tools that include 
direct investments in life sciences companies; grants 
to academic organizations and medical centers and 
grants for “shovel ready” public and non-profit sector 
capital projects that help influence the location deci-
sions of life sciences companies.
n The MLSC operates under a Board of Directors that 
includes state government officials, industry CEOs, 
leaders from academia and medicine, bioscience 
researchers and others who have great knowledge of 
the life sciences.
n Investments are reviewed by a panel of more than 
200 experts who send their recommendations to the 
Center’s Scientific Advisory Board, which itself is 
dominated by academic researchers, industry scien-
tists and private venture capital experts who together 
can judge the scientific and economic potential of an 
MLSC investment. 
n The Center insists on accountability in terms of 
private sector investment matches and specific job 
creation goals and retains the power to “claw back” 
tax incentives and other investments when these 
goals are not reached by grant recipients.51
In the four-year period between June 2008 and June 2012, 
the Center invested nearly $190 million in 12 capital proj-
ects, provided 31 company grants and loans worth nearly 
$23 million, issued 35 academic research grants with a 
value in excess of $23 million and 56 tax incentives (still 
outstanding) valued at close to $57 million, invested $7 
million to fund 884 interns as part of the Center’s mission 
to help develop the life sciences workforce, provided 
more than $3.3 million in equipment and supply grants 
to schools and spent $1.5 million on other grants includ-
ing the funding of business plan competitions. As of June 
30, 2012 the Center was managing a portfolio of approxi-
mately 200 grants, loans, and tax incentives.52
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This comprehensive approach to an entire industry 
cluster differs significantly from other federal, state, and 
local incentive programs that target a single company or, 
at best, a single industry. 
We can now ask: “Has this approach, and the investments 
made through the MLSC, paid off?” 
We begin to answer this question by tracking output and 
employment in the life sciences cluster and consider the 
results in terms of the creation of the Center in 2006.
But given what we have learned about the role of 
innovation in spurring economic growth, we can ask 
a more fundamental question. “Has the creation of 
the Center and the Life Sciences Initiative paid off in 
terms of nurturing a rich ‘ecosystem’ within which the 
entire life sciences super cluster can flourish now and in 
the future, providing a platform for further growth in 
economic opportunity for Massachusetts residents?” 
MLSC Scientific Advisory Board. The company has 
already been able to launch its first commercially viable 
product for help in diagnosing cancer, neurological 
disorders, and other diseases. 
Examples of matching grants for academic research 
include:
n $5.1 million in grants to early career investigators 
working in research institutions within the Common-
wealth which have in turn helped generate over 
$13 million in federal government, foundation, and 
private company research grants 
n $4.8 million in cooperative research grants (between 
2008 and 2011) to encourage industry-sponsored 
research at Massachusetts institutions, resulting in 
more than $8.6 million in research grants from other 
sources
Examples of the $20.6 million in 2011 program tax incen-
tives to 26 life sciences companies include $3 million to 
Shire HGT, Inc.; $2.45 million to Vertex; $2.3 million to 
AVEO Pharmaceuticals; and $1.84 million to Biogen Idec 
MA, Inc. Smaller tax incentives of less than $500,000 
went to such firms as Blueprint Medicines Corporation 
in Cambridge and T2 Biosystems, Inc. in Lexington. 
Under the Life Sciences Act, the Department of Reve-
nue has the authority to “claw back” incentives from 
companies that the Center determines have not met the 
minimum job creation thresholds in their tax-incentive 
agreements.
In addition, the MLSC Internship Challenge Program 
has placed more than 1,000 interns in more than 290 
companies across the state where host companies 
provide dedicated mentors to help expand the pool 
of prospective life sciences workers for the future. 
Those college students receiving MLSC internships are 
majoring in biology, engineering, chemistry, business, 
computer science and physics and end up interning in 
companies that produce medical devices, pharmaceu-
tical products, diagnostic services, and biotechnology 
research. In FY2012, the Center also awarded $180,000 
to four programs to encourage science, technology, 
engineering and math (STEM) education, especially 
for women and minorities. 
Table 3 provides a summary of the investments made 
by the MLSC between June 2008, when the Life Sciences 
Initiative funding first became available, and June 2012.
TABLE 3 
Distribution of MLSC Investments by Dollar Amount 
 June 2008–June 2012
Capital Projects (12) $186,950,000
Company Grants and Accelerator Loans (31) $22,907,000
Academic Research Grants (35) $23,346,344
Tax Incentives (56) $56,595,093
Interns Funded for Workforce  
Development (884) $6,903,164
Equipment and Supply Grants  
or Schools (32) $3,333,675
Other Grants/Business Plan Competitions $1,540,000
Total $301,575,276
Source: Massachusetts Life Sciences Center, 2013
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CHAPTER SIX
Output and Employment in the Massachusetts  
Life Sciences Super Cluster
The life sciences super cluster began to benefit the 
Commonwealth by the middle of the last decade, even 
before the MLSC was established. By 2006, publicly 
traded companies in Massachusetts were already gener-
ating $30 billion in sales, an increase of nearly 50 percent 
in just four years. With $7.5 billion in exports, the Massa-
chusetts life sciences sector accounted for 30 percent  
of total state exports.53 Between 2001 and 2006, employ-
ment in Massachusetts life sciences industries increased 
by 13,000—more than 16 percent. The life sciences were 
generating jobs during a period when total non-farm 
employment in Massachusetts was actually declining by 
2.8 percent. While total employment in the life sciences 
in 2006 accounted for just 26 out of every 1,000 jobs in 
the state, this sector was growing faster than any other, 
including education and health services (See Figure 4).
As Figure 5 reveals, the life sciences cluster continued 
to generate jobs between 2006 and 2011, but not quite 
as rapidly as during the previous five years. However, 
it was still faster than every other sector save education 
and health services. The national recession that began at 
the end of 2007 weighed on the life sciences sector, as it 
did most other industries. Life sciences remained a small 
sector in terms of overall non-farm state employment, 
but given its faster growth, accounted for nearly 30 jobs 
out of every 1,000 in the Commonwealth by 2011.
Taking the entire decade (2001–2011) as a whole, the life 
sciences far outpaced all other industry sectors in terms 
of its employment growth rate as shown in Figure 6. 
Within the cluster, however, the growth in employment 
has varied greatly across individual industry segments 
as shown in Table 4. During the entire period between 
2001 and 2011, employment in research, testing, and 
medical laboratories increased by more than 50 percent, 
nearly twice as fast as the life sciences cluster as a 
whole (and 2½ times as fast as education and health 
services). Yet the production of medical devices—the 
FIGURE 4
Massachusetts Employment Growth by Industry Sector  
2001–2006
Source: Bureau of Labor Statistics, Author’s Analysis
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What is notable, however, is that the employment 
growth rate actually increased in the second period 
(2006–2011) for both the pharmaceutical industry and 
key manufacturing segment of the life sciences cluster 
—remained nearly constant over this period, increasing 
by just 0.2 percent.
FIGURE 5
Masssachusetts Employment Growth by Industry Sector  
2006–2011
Source: Bureau of Labor Statistics, Author’s Analysis
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FIGURE 6
Massachusetts Employment Growth by Industry Sector  
2001–2011
Source: Bureau of Labor Statistics, Author’s Analysis
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employment trends reveal that the Commonwealth 
has indeed overtaken the rest of the nation in terms of 
employment growth in the life sciences, fulfilling the 
initial goal of the MLSC. 
Figure 7 reveals the trend in life sciences employment in 
Massachusetts compared to that of the nation as a whole 
between 2001 and 2011. During this period, Massachu-
setts life sciences employment growth outperformed  
the nation by a factor of better than 2-to-1—growing by 
27.3 percent vs. 11.9 percent for the nation. 
Figure 8, which indexes employment growth to 2007, 
reveals how the Commonwealth’s life sciences cluster 
grew at a faster clip than the nation’s, surpassing the 
nation and now remaining firmly ahead of it in terms of 
employment growth.
medical device manufacturing, despite recession condi-
tions nationally and regionally. Indeed, all four sectors 
in Table 4 exhibited increased employment during this 
difficult economic period. 
Life Sciences Employment Trends: 
Massachusetts vs. the United States
The capacity of the Commonwealth’s life sciences to 
create jobs at a faster pace during the past decade than 
all other major Massachusetts industries is one indica-
tor of the successful development of this sector. Even 
more important is how the state’s life sciences have 
performed relative to the country as a whole and other 
states vying for supremacy in this rapidly evolving 
cluster of industries. The data we have gathered on 
FIGURE 7
Employment in Life Sciences Indexed to 2001,  
Massachusetts vs. the U.S.
Source: Author’s Analysis from BLS data
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FIGURE 8
Employment in Life Sciences Indexed to 2007,  
Massachusetts vs. the U.S.
Source: Author’s Analysis from BLS data
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TABLE 4 
Employment Change by Life Sciences Cluster Segment
2001 2006 2011 % Δ2001–2006 % Δ2006–2011 % Δ2001–2011
Drugs & Pharma 7,794  7,944  8,537  1.9% 7.5%  9.5%
Medical Devices & Equipment 22,835 21,645 22,882 –5.2% 5.7%  0.2%
Research, Testing, & Medical Labs 34,849 47,072 52,819 35.1% 12.2% 51.6%
Bioscience-Related Distribution  9,607 10,877 11,377 13.2% 4.6% 18.4%
Total 75,085 87,538 95,615 16.6% 9.2% 27.3%
Source: Bureau of Labor Statistics, Author’s Analysis
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the life sciences super cluster. In 2011, the Common-
wealth boasted more than 28,000 jobs, exceeding second 
place California (22,600) and third place Pennsylvania 
(11,200).54 Since 2007, this particular sector grew faster 
in the Commonwealth than in any other state, adding 
more than 3,500 jobs.
When we control for population size, Massachusetts 
is the clear winner for the entire life sciences cluster of 
industries. In Figure 10, we have controlled for the size 
of population of each state by measuring the number 
of life sciences jobs per 1 million residents. In 2001, the 
District of Columbia actually had the highest per capita 
number of life sciences jobs, presumably because of the 
physical presence of the National Institutes of Health. 
Delaware ranked second followed by New Jersey. 
California actually lagged Minnesota, Utah, and New 
Mexico on this measure. Massachusetts ranked #4.
But by 2011, given its rapid growth rate, the Massachu-
setts cluster had risen to #1 in terms of per capita life 
sciences employment. With nearly 14,300 life sciences 
jobs per 1 million people, Massachusetts had eclipsed 
New Jersey (12,171) and continued to far outstrip  
California (8,300). 
The Commonwealth’s main competitors in the life 
sciences include California, New Jersey, New York, 
Florida, and Texas. But as Figure 9 demonstrates, after 
2008 the Commonwealth overtook all of these states 
in terms of its 2001–2011 employment growth rate. 
Florida’s nascent life sciences sector had been growing 
faster, but has fallen behind the Bay State during the 
past four years. Texas has been trying to catch up, but 
still trails Massachusetts. Over the decade, California’s 
life sciences employment grew by just 18.4 percent 
compared with the Commonwealth’s 27.3 percent. The 
growth rate in New York has been anemic, adding only 
2 percent to its life sciences workforce while New Jersey, 
once the pharmaceutical capital of the nation, has seen 
its life sciences cluster decline sharply since 2007.
Even with Massachusetts’s #1 position in the life 
sciences employment growth rate, it is not surprising 
that other states still have a larger absolute number of 
life sciences jobs. Of the top six states, Massachusetts 
ranked 5th in 2011, as Table 5 reveals. California leads 
the pack with nearly 310,000 life sciences jobs. 
Yet even as a much smaller state in total population, 
Massachusetts now leads all other states in the number 
of jobs in the vital biotechnology R&D sector within 
FIGURE 9
Employment in Life Sciences Indexed to 2001,  
Massachusetts vs. Big Competitor States
Source: Author’s Analysis from BLS data
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FIGURE 10
Life Sciences Jobs per 1 Million 2010 Population
Top 8 States in 2011, by Year
Source: Author’s Analysis from BLS data
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Clearly, the life sciences cluster has enjoyed stellar 
growth in the Commonwealth over the past decade, and 
it appears that after the MLSC was created, the pace of 
growth outdistanced all of Massachusetts’s rivals. 
Clearly, the life sciences are flourishing in Massachu-
setts and the timing of the sector’s employment growth 
suggests at least a correlation between the creation of 
the MLSC and the ability of the state’s life sciences super 
cluster to overtake the rest of the nation. 
But what evidence do we have of causation rather than simply 
correlation? What role has the MLSC played in the stellar 
growth of this set of industries? Here we find the interviews 
we conducted with key informants provided additional infor-
mation on the role MLSC has played in this 21st-Century 
story of industrial success. 
TABLE 5 
States with Largest Life Sciences Employment (2011)
California 309,344
New York 109,750
New Jersey 107,007
Texas 96,969
Massachusetts 95,615
Florida 83,836
 Source: Author’s Analysis from BLS data
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community of life sciences institutions including univer-
sities, research hospitals, small start-up bioscience 
firms, medical device manufacturers, and Big Pharma. 
These stakeholders all interact on a regular basis to 
assist each other in the promotion of their activities. 
The ecosystem includes the nurturing of small firms 
through the MLSC’s accelerator-loan and tax-incentive 
programs, assistance to the life sciences research labs in 
the state’s public higher education system, the provi-
sion of funds for student interns in relevant fields, and 
countless opportunities for executives, scientists, and 
industry employees to meet and explore opportuni-
ties for expanding the life sciences super cluster in the 
Commonwealth. The Center has been critical, according 
to our key informants, in helping to build a “platform” 
for the entire sector and cultivate a “collaborative gene” 
among all of its separate parts.
As one recent example of this role, the MLSC helped 
create the Massachusetts Neuroscience Consortium, 
announced at the 2012 BIO International Convention in 
Boston. With charter sponsors including Abbott Labs, 
Biogen Idec, EMD Serono, Janssen Research & Develop-
ment LLC, Merck, Pfizer, and Sunovion Pharmaceu-
ticals, Inc., the consortium provides an arrangement 
whereby companies that normally compete with each 
other collaborate on funding preclinical neuroscience 
research under way at academic and research institu-
tions throughout the state. With leadership provided by 
the MLSC, each of the founding sponsors has pledged 
$250,000 toward this effort, and the Center will admin-
ister the funds.55 The research results will be shared 
with all participants and all companies and academic 
researchers will have access to any tools developed as a 
result of these investigations. Without the Center play-
ing this convening role, it is unlikely that such a consor-
tium would have come into existence.
The Center has also been responsible for helping to 
nurture international cooperation among life sciences 
firms and academic institutions. The Center provided 
a $300,000 grant to the Northern Ireland Massachusetts 
Connection (NIMAC) for a new multinational research 
CHAPTER SEVEN
The Key Role of the MLSC:  
What We Learned from the Interview Data
To obtain a firsthand view of what part the MLSC may 
have played in the emergence of the Commonwealth’s 
life sciences ecosystem, we conducted a series of “key 
informant interviews” with executives in the industry, 
with leaders of related trade associations, and with a 
number of scientists who have an intimate knowledge of 
the range of activities of the Center. In order to obtain an 
honest and unbiased assessment of the $1 billion initia-
tive itself and the functioning of the Center, we assured 
each of our informants strict confidentiality. Interviews 
were carried out with executives in both large and small 
companies in the industry, with those mostly devoted 
to research and development, and with those whose 
companies are now involved with the manufacture of 
scientific and medical products. 
While we probed on many fronts, we asked each infor-
mant to consider a fundamental “counterfactual”: Would 
the life sciences in Massachusetts be much different from 
what they are today if the MLSC had never been created and 
the state had not committed long-term funding to assist the 
array of universities, research institutes, and companies that 
make up the life sciences super cluster? What we learned 
provided us with a vital and deeper understanding of 
the critical role the MLSC has played.
Here are our key findings.
The Development of the Life Sciences 
“Ecosystem”
The leaders of large firms told us that given the scale of 
their operations, the MLSC plays at best a minor direct 
role in their own development, but an immense indirect 
role that helped to attract them to Massachusetts. The 
term that surfaced in virtually all of our interviews is 
“ecosystem,” and that the MLSC has been central to the 
creation of the life sciences ecosystem that has made the 
Commonwealth more attractive than competing regions. 
According to our interviews, the MLSC has indeed 
been instrumental in bringing together a tight-knit 
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panoply of small start-up firms. The reason for this is that 
despite their substantial research budgets, even the 
largest of the life sciences companies do not have the 
resources to generate more than a handful of break-
through innovations in the biosciences, genomics, and 
other sophisticated fields. These large firms grow and 
prosper by carefully monitoring the scientific discover-
ies under way in university research laboratories and in 
the translational research carried out by small start-up 
firms. Those few start-ups that end up with potential 
blockbuster drugs or devices become prime targets for 
acquisition by the larger firms. Only a fraction of the 
long-term revenue generated by Big Pharma and the 
largest biotech and medical device companies has its 
origin in their own research labs. The majority comes 
from the absorption of successful smaller firms.
The secret to success in the acquisition process is being 
where the small firms are located. This permits the 
large firms to closely monitor the progress of smaller 
firms and buy the most promising ones before other Big 
Pharma or other competitors can make a bid. To use 
a metaphor from nature, the large, globally important 
life sciences firms want to feed in the waters where the 
minnows are swimming.
Pfizer, for one, has moved operations into Cambridge 
from other locations for this purpose.56 In 2010, it 
announced that Cambridge would become one of Pfiz-
er’s worldwide research and development hubs, and it 
relocated approximately half of the current employees 
from its BioTherapeutics R&D organization to Kendall 
Square. A year later, Pfizer announced plans to move 
two existing research units, Cardiovascular Medicine 
(CVMed) and Neuroscience from Groton, Connecticut, 
to Cambridge, leasing 180,000 square feet of lab and 
office space from MIT to house these two research units. 
In June 2011, Pfizer opened the Boston Centers for Ther-
apeutic Innovation (CTI), an entrepreneurial network 
of partnerships with leading academic medical centers. 
According to the company, “these partnerships reduce 
the time and cost of drug discovery and development by 
accessing leading translational researchers.”57 Boston is 
also the global headquarters for the CTI network, which 
has established partnerships in New York City and San 
Francisco. The richness of the Massachusetts life sciences 
ecosystem prompted Pfizer to expand still further in the 
Commonwealth, with the company’s newest building in 
Cambridge scheduled to be completed in 2013. 
study on non-invasive procedures to detect pre-malig-
nant lesions. Finland and Catalonia have joined NIMAC 
as well. MLSC is also helping to develop alliances 
between Massachusetts companies and Israeli firms 
through the Massachusetts-Israel Innovation Partner-
ship (MIIP). The Center has contributed $300,000 to this 
effort so far, funding two Massachusetts firms working 
in partnership with Israeli firms. A second round of 
funding for this program is pending.
All of these efforts are part of building an ever larger life 
sciences ecosystem based in the Commonwealth. 
The Unique Growth Pattern of Regional  
Life Sciences Clusters
The most important lesson we derived from our inter-
views, however, was the unique growth pattern of the 
life sciences cluster. The regional concentration of life-
sciences companies happens in a very different manner 
than in other industries. In the case of traditional 
industrial sectors such as auto, aircraft engine, financial 
services and the like, a region becomes dominant in a 
particular cluster once a large anchor enterprise or a 
small number of them establish operations in that locale. 
Once the anchor enterprise is established, an array of 
smaller firms is attracted to that region to serve as part 
of the supply chain for the large anchor enterprise(s). 
Once Detroit became home to Henry Ford’s car 
company and General Motors and Chrysler built huge 
auto assembly facilities in Michigan, hundreds of small 
parts plants, design studios, and small engineering 
facilities opened their doors nearby in order to easily 
serve the industry’s “Big Three.” The same is true of the 
aircraft engine industry in New England dominated by 
Pratt & Whitney in East Hartford, Connecticut,  
and General Electric’s Aircraft Engine facility in  
Lynn-Everett, Massachusetts. These massive facilities 
attracted hundreds of aircraft engine parts suppliers 
to New England, making the region one of the core 
jet-engine manufacturing centers in the United States. 
Essentially, the small firms in the industry are dependent on 
the large ones.
For the life sciences, the reverse is true. For companies 
that crucially depend on the development of break-
through innovations and sophisticated medical devices, 
the large firms prosper by reason of being proximate to a 
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The lack of easy access to VC funds has worried small 
life sciences firms about the “valley of death”—the 
gap in funding needed to move basic research into 
commercial products. In this environment, the MLSC 
has become an important investment partner for smaller 
life sciences firms, providing them with funds for trans-
lational research and development. These smaller firms 
may grow out of local research universities and medi-
cal complexes, but they can then turn to the MLSC for 
investment assistance. This tends to help keep them in 
the Commonwealth instead of losing them to invest-
ment funds in other regions. 
In a number of cases, we found that smaller companies 
were being lured to relocate to other states, but accord-
ing to their executives, the MLSC moved quickly to 
narrow the interregional cost differential and keep these 
firms in the Commonwealth. They did this through tax 
incentives and investment credits. And because these 
“minnows” stay here, Big Pharma has come from all 
over the world to swim in this pond. By helping to 
attract small life sciences companies to Massachusetts 
as well as incubating new ones begun in the state, the 
MLSC has created a well-stocked fishing ground for 
Big Pharma. In 2012 alone, a large array of small- and 
medium-sized domestic and international firms chose 
to establish operations in Massachusetts, including Era7 
Bioinformatics, Algeta U.S., QServe, Scivax USA, Repro-
CELL, Inc., Human Metabolome Technologies, Inc., 
Alacrita, Arrayjet, ARGO Medical Technologies, BioAx-
one, BioSurplus, Promedior, and KeraFAST.
By the end of 2012, nine of the ten major drug compa-
nies in the world had set up shop in Massachusetts.61 
To house these firms, 3.4 million square feet of biotech-
related office and laboratory space is now under 
construction across Massachusetts with massive build-
ings now being completed for Pfizer and Novartis. This 
adds to the 2.4 million square feet of commercial lab 
space erected between 2007 and 2011.62 The other Big 
Pharma firms with major investments in Massachusetts 
are Johnson & Johnson, GlaxoSmithKline, Sanofi (which 
absorbed Genzyme), AstraZeneca, Abbott Laborato-
ries, Merck, and Bristol-Myers Squibb. A decade ago, 
none of these global firms had a significant presence or 
any presence at all in the state, according to Mass Bio, 
the state’s life sciences trade group.63 Only Roche, the 
Swiss company and third largest biopharmaceutical 
firm in the world, has yet to establish a presence in the 
Commonwealth. 
Over the past three years, Massachusetts is the only state 
where Pfizer has added jobs, not California, Connecti-
cut, New Jersey, or New York. As an executive of this 
company told us in one interview, “Innovation between 
the big, the small, and the in-between is what makes 
the industry succeed.” Another Pfizer executive noted 
that while his company has not taken a dollar from the 
MLSC, the Center has helped the firm by creating a 
“mentality” about the life sciences that has permeated 
the state right down to the local level, making it possible 
to speed local permitting and rezoning where necessary. 
Executives at Sanofi-Aventis SA, which acquired 
Genzyme in 2011 in a $20 billion deal, have relied on the 
MLSC to “act as a bridge” between the company and 
such research institutions as the Cummings School of 
Veterinary Medicine at Tufts University and the Univer-
sity of Massachusetts Medical Complex in Worcester. 
Like Pfizer, Sanofi is expanding in Cambridge in order 
to have a “front row seat” for acquisitions.58
And here is the key to understanding the central role 
of the MLSC. While the large firms can easily exist without 
the MLSC, the small life sciences firms need the Center to 
provide them with accelerator loans, research and development 
funds, and interns who can help them translate their ideas 
into what could be commercially viable products. While the 
private venture capital market may provide some funds for 
this purpose, venture capital often requires a quicker return 
than can be obtained from this industry, which often has long 
lag times between initial research, proof of concept, and a final 
FDA-approved product. 
In 2012, according to data gathered by Pricewater-
houseCoopers, venture capital investments in biotech 
and health-care startups fell to their lowest level since 
1995.59 Investment in biotech firms in the Boston area 
dropped to $869 million in 2012, a 24 percent reduc-
tion from 2011 levels. Regulatory uncertainty facing the 
health-care industry is making this “a more challenging 
time for life sciences companies to raise money,” accord-
ing to Terry McGuire, general partner of Polaris Venture 
Partners, a Waltham-based VC firm with about half its 
portfolio invested in health-care companies.60 Another 
reason biotech investments may be dwindling is that 
new software companies are on the rise and the return 
on investments in these firms tends to be much more 
“capital-efficient,” paying off relatively rapidly.
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It should be noted that other states that have created 
similar life sciences initiatives have had a less-than-stellar 
record of maintaining a process free of political consid-
erations. In early 2013, the Texas Legislature essentially 
defunded the state’s Cancer Prevention and Research 
Institute (CPRIT), which had been established by refer-
endum in 2007. This followed the resignation of the 
agency’s chief scientific officer, along with many of the 
institute’s high-profile grant reviewers, in protest over 
how the independent peer review system had been disre-
spected.64 According to the chair of the MLSC’s Scientific 
Advisory Board, here in the Commonwealth the Center 
has been scrupulous in following the recommendations 
of the Center’s Board of Directors and the SAB.
This has apparently contributed to the Center’s excep-
tional record of assisting firms that ultimately succeed 
and grow.  Accountability measures implemented by 
the Center have also contributed to the success of the 
Center’s tax program. As Table 6 reveals, the Center had 
With this growth dynamic at work, Massachusetts 
appears well positioned to continue to attract new 
investment in the life sciences cluster.
The MLSC “Modus Operandi”
In the course of this study, many of those interviewed 
commented on the protocols that the MLSC follows in 
carrying out its activities. According to these sources, 
the Center’s success in funding firms is grounded in its 
reliance on a Scientific Advisory Board (SAB) to guide 
the Center’s Board of Directors in determining which 
firms show the greatest promise of economic and scien-
tific success. The Center has established a competitive 
process for securing assistance and the SAB has made 
certain that the process is transparent. Over and over 
again, we heard in our interviews words like “rigorous” 
and “diligent” when describing the processes MLSC 
uses in selecting awardees. 
TABLE 6 
Firms Receiving Tax Incentive Funding (Program Years 2009-2011)—Active Awards
Hiring 
Goal
Hiring 
Actual
% of 
Goal
Hiring 
Potential
2009 Shire 150 153 102% 153
2009 Cubist 58 60 103% 60
2009 Biogen 50 235 470% 235
2009 Merrimack 50 53 106% 53
2009 Lightlab 29 32 110% 32
2009 Constellation 26 21   81% 26
2009 Sepracor 25 108 432% 108
2009 InfraReDX 21 25 119% 25
2009 OmniGuide 18 10   56% 18
2009 Organogenesis 15  26   73% 26
2009 Dyax 15 23 153% 23
2009 Still River 10 18 180% 18
2009 Nova 10 25 250% 25
2009 Infinity 18 14   78% 18
2009 STD Med 10 54 540% 54
2010 Shire 150 141   94% 150
2010 Sanofil 100 101 101% 101
2010 Vertex 90 136 151% 136
2010 NX Stage 50 27   54% 50
2010 Merrimack 50 37   74% 50
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TABLE 6 
Firms Receiving Tax Incentive Funding (Program Years 2009-2011)—Active Awards (continued)
Hiring 
Goal
Hiring 
Actual
% of 
Goal
Hiring 
Potential
2010 Ironwood 37 56 151% 56
2010 Instrumentation Laboratory 30 30 100% 30
2010 Valeritas 18 10   56% 18
2010 Organogenesis 17 44 259% 44
2010 Bluebird 10 13 130% 13
2010 Bind 10 8   80% 10
2010 NormOxys 10 –5  –50% 10
2010 LeMaitre 19 43 226% 43
2010 Foundation Medicine 40 25   63% 40
2010 Lightlab 14 45 321% 45
2010 Nova 10 10 100% 10
2011 Shire 100 100
2011 Vertex 100 100
2011 AVEO Pharma 94     94
2011 Biogen Idec 75     75
2011 Ironwood 75     75
2011 DePuy Othopaedics 50 50
2011 Momenta Pharma 50 50
2011 PerkinElmer 50 50
2011 Organogenesis 35     35
2011 Aegerion Pharma 27     27
2011 Lightlab 26     26
2011 Cell Signaling Tech 20 20
2011 Quanterix Corp 19 19
2011 NinePoint Medical 15 15
2011 Pharmalucence 12     12
2011 Metamark Genetics 11     11
2011 New England Biolabs 10     10
2011 Nova 10 10
2011 T2Biosystems 10 10
2011 Boston Heart Diagnostics 31 31
2011 Ra Pharma 10     10
2011 Blueprint Medicines 15     15
2011 PAREXEL International 32     32
2011 Moderna Therapeutics 13 13
2011 Courtagen Life Sciences 13 13
2011 Knome 12 12
2009–2011 Awardees 1,160 1,578 136%* 2,639**
 Source: Massachusetts Life Sciences Center
* Proportion of hiring goal for 2009–2010 active awardees only; no data available on 2011 awardees at this time
** Minimum total jobs created if, on average, all firms meet or exceed hiring 
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of the program. The outstanding amount of the tax 
incentive awards as of June 30, 2012 amounts to $15.25 
million. Fifteen firms received tax incentive awards in 
that year totaling $15.25 million. They ranged in size 
from $6.3 million to Shire Human Genetic Therapies 
to $121,000 to STD Med, Inc. In 2009, these firms had a 
base headcount of 5,427. The target headcount associ-
ated with these awards was 5,932—an increase of 505 
hires. By the end of 2011, 12 of these firms had met or 
exceeded their hiring targets. 
What adds to the efficiency of these awards is a “claw-
back” feature requiring firms that fail to meet their 
approved hiring goals to return to the Center the funds 
they were provided. A number of firms have done just 
that when they were unable to meet their specified mini-
mum job-creation targets.
31 outstanding tax incentive packages from the 2009 and 
2010 programs as of June 30, 2012.
In a number of cases, hiring targets were exceeded by 
a factor of four or greater. In only one case did a firm 
receiving an award actually reduce its staff. As of June 30, 
2012, the currently active 31 awards from the 2009/2010 
program have produced 1,578 new jobs, exceeding the 
aggregate hiring goal of 1,160 by 36 percent. Adding in the 
2011 program awards for which we do not yet have data 
on hiring, the potential number of new hires could exceed 
2,600 if all firms, on average, meet or exceed hiring goals.
As noted above, the accelerator loan program is also 
meeting with success, with six of the 20 firms that 
received such loans already repaying them in full. 
Table 7 provides additional data on the outstanding 
awards to firms from the 2009 program, the first year 
TABLE 7
Annual Report: 2009 Tax Incentive Program Results—for annual reporting period ending December 31, 2011
Per Agreement Actual 2011 Actual
$ Award 
Provided
Base 
Hdct Adds Targeted
12/31/2011 
Hdct
Actual 
Growth 
(from base)
% of 
Adds 
(from base)
Achieved or 
exceeded 
target
  COMPANY          
Active awards
1 Shire Human Genetic Therapies, Inc.  $6,277,057   986 150 1136  1280   294 196% Yes
2 Cubist Pharmaceuticals, Inc.  $1,740,000   355 58  413  415   60 103% Yes
3 Biogen Idec MA, Inc.  $1,500,000 1899 50 1949  2134   235 470% Yes
4 Merrimack Pharmaceuticals, Inc.  $1,500,000  124 50  174  214   90 180% Yes
5 LightLab Imaging, Inc.  $188,951   64 29   93  141   77 266% Yes
6 Constellation Pharmaceuticals, Inc.  $513,252   41 26   67  62   21  81% No
7 Sepracor Inc. / Sunovion  $750,000  601 25  626  709   108 432% Yes
8 Infraredx, Inc.  $630,000   60 21   81  85   25 119% Yes
9 OmniGuide, Inc.  $ 540,000   62 18   80  72   10  56% No
10 Infinity Pharmaceuticals, Inc.  $ 540,000  172 18  190  186   14  78% No
11 Organogenesis Inc.  $ 245,240  241 15  256  311   70 467% Yes
12 Dyax Corp.  $ 100,000   94 15  109  117   23 153% Yes
13 Mevion (formerly Still River Systems), Inc.  $ 300,000   73 10   83  91   18 180% Yes
14 Nova Biomedical Corporation  $ 300,000  498 10  508  533   35 350% Yes
15 STD Med, Inc.  $ 121,000  157 10  167  211    54 540% Yes
TOTALS  $ 15,245,500 5427 505  5932  6,561 1,134
Source: Massachusetts Life Sciences Center
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Based on estimates from the Massachusetts Department 
of Revenue, we estimate that, on average, the added 
workers employed by these firms paid more than $4,900 
in income taxes to the Commonwealth and $2,400 in 
sales taxes.65 Assuming that each of these jobs lasts on 
average just five years, the added state revenue gener-
ated by these workers over that period is close to $37,000 
per worker or a total of $93 million in tax revenue.
Compared with the total cost of the incentive program, each 
dollar in awards will generate $1.66 to the state in added tax 
revenue. This represents an extraordinary rate of return 
on this public investment.
Based on wage and salary data from the companies 
receiving tax-incentive awards between 2009 and 2011, 
we carried out an economic analysis of the cost and 
benefit of this MLSC program. The results are found in 
Table 8. Our analysis suggests that as of June 30, 2012, 
the Center had $56.3 million in outstanding tax incen-
tives. Altogether, the firms receiving these incentives 
added more than 2,500 jobs by 2012. The vast majority 
(1,843) of these were in pharmaceutical firms with the 
remainder generated by medical device companies (481) 
and scientific research enterprises (213). The average 
annual salary of these jobs exceeded $105,000. As such, 
these new jobs generated a total of over $266 million in 
wages and salaries each year. 
TABLE 8 
Economic Return on the MLSC Tax Incentive Program
Program Year 
 2009
Program Year 
2010
Program Year 
2011
3 Years of 
 Incentives
Total Value of MLSC Tax Incentives ($) $15,245,500 $20,672,638 $20,340,884 $56,259,022
Net New Jobs Created 901 721 915 2,537
Tax Incentive per Job ($) $22,175
Annual Tax Incentive per 5-year job ($) $4,435
Average Salary per Job ($) $105,037
Total Salaries Generated per Year ($) $266,479,399
State Income Tax Revenue per Job per year ($) $4,937
Total State Income Tax per year ($) $12,524,532
Average Sales Tax per Job ($) $2,404
Total State Sale Tax per year ($) $6,099,447
Total Income+Sales Taxes per year ($) $18,623,979
Average Income+Sales Tax/Job per year $7,341
Total Income+Sales Taxes per 5-year Job $36,705
Total Income+Sales Taxes over 5 years $93,120,585
Net State Revenue Gain (5 years) ($) $36,860,872
Ratio of Tax Revenue/Incentive over 5 years   1.66
Pharma Medical Devices
Scientific  
Research Total
Jobs 1,843 481 213 2,537
Average Salary ($) $115,222 $66,913 $103,009 $105,037
Total Salary ($) $212,353,256 $32,185,280 $21,940,863 $266,479,399
Share of Salary 0.7969 0.1208 0.0823 1.0000
State Income Tax By Sector ($) $9,980,603 $1,512,708 $1,031,221 $12,524,532
Sales Tax by Sector ($) $4,860,554 $736,689 $502,204 $6,099,447
Source: Dukakis Center for Urban and Regional Policy
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FIGURE 11
Education Distribution of New Hires 
by 2010 MLSC Tax Incentive Awardees 
Source: Dukakis Center for Urban and Regional Policy
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Education Distribution—Diagnostics, Tools, 
 and Related Products and Services
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Of course, it is possible that these firms would have 
generated some or perhaps even many of these jobs with-
out the MLSC award. But given the importance of the 
life-sciences ecosystem created in the Commonwealth, 
at least partly as a result of Center activity, it is reason-
able to suggest that many of these jobs and their associ-
ated tax revenue would not have been created without 
the help of the Center. Moreover, our estimates do not 
consider any “multiplier” effects. The added spending 
of these new hires in the Commonwealth helped gener-
ate additional jobs as these workers spent money in the 
state, creating jobs in a wide range of industries. 
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educated workers, these firms need laboratory techni-
cians and clerical staff, and they employ a range of other 
workers in occupations that require a good deal less 
education. Figure 11, based on these hiring data, reveals 
that less than a third (29%) of those working in the life 
sciences have a Master’s degree, professional degree, 
or Ph.D. Nearly half (48%) have the B.A. or B.S. as their 
highest level of education, while nearly a quarter (23%) 
of the workforce has no more than an associate’s degree, 
often from a community college.
Using national data from the 2010 American Community 
Survey (ACS) available from the U.S. Census Bureau, we 
were able to estimate the education distribution for the 
individual sectors within the life sciences super cluster. 
As Figures 12–15 demonstrate, the proportion of work-
ers in each of the cluster segments needing less than 
a B.A. (or B.S.) ranges from 21 percent in diagnostics, 
tools, and related products and services and 22 percent 
in pharmaceutical firms to more than half in medi-
cal devices. According to these national estimates, the 
total workforce in the super cluster requiring less than 
a 4-year college degree is 30 percent, a bit higher than 
the 23 percent in Massachusetts. Essentially, with such a 
highly educated workforce in the Commonwealth, firms 
here are able to insist on somewhat higher educational 
credentials for their employees. 
What adds to the value of the life sciences labor market 
in the Commonwealth are the high wages paid in 
this sector. As Table 9 reveals, based on an analysis of 
Census data, the average annual wage in the state’s 
A concern that one might have about the employment 
generated by the life sciences super cluster is that the 
jobs created all go to the most educated workers in 
the state, leaving behind those who have not had the 
benefit of a college degree or post-graduate education. 
But based on the hiring records of a number of firms in 
the industry, it turns out that like other industries, life 
sciences firms need to hire workers who have a range 
of skills. In addition to Ph.D. scientists and other highly 
FIGURE 15
Education Distribution—Life Sciences Cluster 
Pharma/Medical Devices/Diagnostics, Tools,  
and Related Products and Services
Source: Dukakis Center for Urban and Regional Policy
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TABLE 9
Estimated Annual Earnings for Life Sciences Workers 
(2006–2010)
Pharma Medical Devices Scientific R&D Total
Less than High School graduate $35,142 $51,685 $36,702
HS graduate $42,966 $33,250 $71,418 $44,225
Some college, no degree $62,745 $46,684 $61,816 $55,386
Associate’s degree $96,171 $61,400 $53,712 $61,285
Bachelor’s $95,147 $98,853 $85,080 $92,033
Master’s $102,851 $114,019 $102,045 $105,143
Professional school degree $150,264 $118,399 $182,999 $161,195
Doctorate $171,596 $249,332 $112,626 $134,195
Total $102,961 $78,498 $96,379 $91,805
Source: Dukakis Center Analysis of American Community Survey (Census) data
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 The big question is whether Massachusetts can continue 
to lead the nation in the evolution of this critical indus-
try or whether other regions of the country will be able 
to capture this industry and the jobs that go with it. 
Massachusetts was once the premier textile center of the 
nation until the south captured much of the industry in 
the early part of the 20th century. The Commonwealth 
led in the development of the commercial computer 
industry in the 1970s and 1980s with the growth of Digi-
tal Equipment Corporation (DEC), Data General, Prime 
Computer, and Wang, but lost out to Silicon Valley in 
California and companies like Dell in Texas. Today, other 
states including New Jersey, California, New Mexico, 
Utah, and Minnesota are all vying to expand their life 
sciences clusters.The state’s concentration of globally 
prominent “eds and meds” has clearly been critical to 
the evolution of the life sciences in the Commonwealth. 
One area where the MLSC might wish to pay more 
attention in the years to come is the medical-device 
industry. As noted earlier in this report, employment in 
this component of the life sciences cluster has been stag-
nant. According to our interviews, other states includ-
ing Indiana, Michigan and Minnesota are targeting this 
sector with state funding. Unlike Big Pharma, which 
can be more patient in the marketplace and worry less 
about cost pressures, medical-device firms need to move 
quickly in the market to commercialize their products 
and they need to be vigilant about reducing costs. To the 
extent that the MLSC can assist these firms, Massachu-
setts could remain a center for this sector and employ-
ment growth could ensue.
But overall, based on the state’s continued commitment 
to the life sciences, we fully expect to see further growth 
in the size of private-sector investments in the state’s life 
sciences industries and further increases in employment 
opportunity.
Assessment of the MLSC Staff
The interviews we carried out also suggested that the 
Center itself is being run quite effectively and efficiently 
and in a highly professional manner. Virtually all of our 
informants praised the management team and especially 
appreciated the leadership’s reliance on peer review 
and its refusal to permit political considerations to 
trump scientific merit. As one expert informant noted, 
the MLSC has “lots of moving parts” and all of them 
are working well and the Center remains responsive to 
life sciences varies from $78,500 in medical devices to 
nearly $103,000 in the pharmaceutical industry.66 Those 
with a Ph.D. earn, on average, nearly $250,000 in the 
medical-device sector and well over $100,000 in other 
sectors within the cluster. But even those who have not 
completed high school average nearly $37,000 a year, 
the equivalent of more than $18.00 an hour. High school 
graduates average more than $44,000 and those with an 
associate’s degree, more than $61,000. 
Compared with other industries, the life sciences 
provide some of the highest paying jobs in the 
Commonwealth. With an average annual salary of 
nearly $92,000, this sector rewards its workforce with 
higher pay than those who work in manufacturing as a 
whole, construction, real estate, education, government, 
health care, and transportation. The average salary 
in the life sciences industries in the Commonwealth 
exceeds the all-industry Massachusetts average by  
68 percent.67
The Long-Term Impact of the 
Commonwealth’s Life Sciences Initiative
Based on all of the data we collected about the MLSC 
and its activities, the analysis we conducted on the 
expansion of the life sciences industries in the Common-
wealth, and the information we gleaned from the 
interviews, our overall conclusion is that because of its 
unique comprehensive approach to an entire industry 
super cluster and its reliance on scientific peer-reviewed 
procedures for awarding grants, the Commonwealth 
has reaped a substantial return on its life sciences initia-
tive investment. Moreover, given the number of firms 
that have been attracted to the state, in large measure 
because of the ecosystem the Center has helped nurture, 
the benefits from the state’s investment in this initiative 
are likely to pay off bountifully in the years to come. 
Many of our informants for this report noted that by 
2018, when the $1 billion Life Sciences Initiative sunsets, 
the state will still need an agency that encourages inno-
vation among smaller life sciences firms. Innovation, 
they note, must be a continuous process for the region to 
remain prosperous. This will be particularly important 
as China, India, Singapore, and other foreign countries 
compete for a share of this expanding super cluster by 
offering massive incentives to life sciences start-ups. 
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industry needs, meeting deadlines, and staying focused 
on its mission. As another informant put it, with the 
reliance on the Scientific Advisory Board (SAB) to select 
awardees, “there is not an ounce of boondoggle in this 
agency.” In its report on creating fiscally sound state 
tax incentives, the Pew Center on the States singled out 
the Massachusetts Life Sciences Tax Incentive Program 
for its focus on annual cost controls and its reliance on 
scientific merit in making awards.68
Still another informant noted that the MLSC is success-
ful because its leadership is committed to working 
“at the speed of business” and therefore has become a 
valued partner in the expansion of the industry. 
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4. Helping fund workforce development efforts for 
critical industries as part of the mandate of the quasi-
public helps assure a pipeline of skilled workers for 
the industry and this itself helps attract new firms to 
the region.
5. Taking a “portfolio” approach to the entire range of 
activities in the life sciences—from investments in 
small innovative firms to helping train the future 
workforce to underwriting infrastructure—helps 
sustain the “ecosystem,” undergirding a virtuous 
cycle of discovery, innovation, investment, and 
employment opportunity. 
In the end, we applaud the Governor and the Legisla-
ture for their foresight in creating the Massachusetts Life 
Sciences Center and the $1 billion Life Sciences Initia-
tive. The structure put in place is fulfilling the goals set 
out in the original legislation and the Center’s leader-
ship has continually assured that the structure works 
effectively and efficiently.
Conclusions
All of our research suggests that the state will benefit 
from fully funding the remaining five years of the initia-
tive in order to maintain the lead the life sciences have 
established in the Commonwealth. This is particularly 
important as other states ramp up their investments 
in hopes of creating their own life-sciences ecosystems 
to entice the small and large firms Massachusetts has 
successfully attracted. California, Maryland, New Jersey, 
New York, Minnesota, and Florida are not resting on 
their laurels, but continue to spend state funds on their 
own life-sciences industries.
Over time, it should be possible for the Center to reach 
out to the private sector to help fund more of its initia-
tives, as it has done with the Massachusetts Neurosci-
ence Consortium. With the plethora of larger, profitable 
firms coming to the state to expand their operations, one 
could imagine the Center funding more of its intern-
ships with private funds and having private firms 
contribute to other programs (STEM education, for 
example), allowing the Center to focus even more of its 
funding on accelerator loans and tax incentives for firms 
undertaking translational research.
We should also note that the success of the MLSC has 
lessons for other quasi-public entities in the Common-
wealth. We can mention five of them here:
1. Long-term success in the use of tax incentives and 
business loans is most likely to occur when funds are 
focused on a cluster of firms and a set of technolo-
gies in a given industry, helping to create an indus-
trial ecosystem which can attract new companies to 
the state. 
2. The use of expert panels to determine the awarding 
of loans assures that these funds will be well utilized. 
“Claw-back” provisions protect the taxpayers by 
requiring firms to repay funds advanced by the 
Commonwealth if they fail to meet hiring goals.
3. The focus on encouraging firms in their early-stage 
innovation activity is central to promoting economic 
growth and prosperity.
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